

EXHIBIT

1

AO 88 (Rev. 02/14) Subpoena to Appear and Testify at a Hearing or Trial in a Civil Action

UNITED STATES DISTRICT COURT

for the
District of Massachusetts

In re Nexium (Esomeprazole)
Antitrust Litigation

Civil Action No. 12-md-02409-WGY

SUBPOENA TO APPEAR AND TESTIFY
AT A HEARING OR TRIAL IN A CIVIL ACTION

To: Keeper of Records, Ranbaxy Inc.
c/o The Prentice Hall Corporation System, Inc., 2711 Centerville Road Suite 400, Wilmington DE 19808
(Name of person to whom this subpoena is directed)

YOU ARE COMMANDED to appear in the United States district court at the time, date, and place set forth below to testify at a hearing or trial in this civil action. When you arrive, you must remain at the court until the judge or a court officer allows you to leave. **See Attachments A and B for further information.**

Place: Clarkson S. Fisher Building & U.S. Courthouse
402 East State Street
Trenton, NJ 08608

Courtroom No.: To be determined
Date and Time: Beginning October 22, 2014 at
9:00 a.m. and every day thereafter until dismissed

You must also bring with you the following documents, electronically stored information, or objects *(leave blank if not applicable)*:


The following provisions of Fed. R. Civ. P. 45 are attached – Rule 45(c), relating to the place of compliance; Rule 45(d), relating to your protection as a person subject to a subpoena; and Rule 45(e) and (g), relating to your duty to respond to this subpoena and the potential consequences of not doing so.

Date: _____

CLERK OF COURT

OR

Signature of Clerk or Deputy Clerk


Attorney's signature

The name, address, e-mail address, and telephone number of the attorney representing *(name of party)* _____
the Direct Purchaser Class Plaintiffs _____, who issues or requests this subpoena, are:

Thomas M. Sobol, Hagens Berman Sobol Shapiro LLP
55 Cambridge Parkway, Suite 301, Cambridge, MA 02142 tom@hbsslaw.com (617) 482-3000

Notice to the person who issues or requests this subpoena

If this subpoena commands the production of documents, electronically stored information, or tangible things before trial, a notice and a copy of the subpoena must be served on each party in this case before it is served on the person to whom it is directed. Fed. R. Civ. P. 45(a)(4).

AO 88 (Rev. 02/14) Subpoena to Appear and Testify at a Hearing or Trial in a Civil Action (page 2)

Civil Action No. 12-md-02409-WGY

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 45.)

I received this subpoena for *(name of individual and title, if any)* _____
on *(date)* _____

☐ I served the subpoena by delivering a copy to the named person as follows: _____

_____ on *(date)* _____ ; or

☐ I returned the subpoena unexecuted because: _____

Unless the subpoena was issued on behalf of the United States, or one of its officers or agents, I have also
tendered to the witness the fees for one day's attendance, and the mileage allowed by law, in the amount of
\$ _____

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ _____

I declare under penalty of perjury that this information is true.

Date: _____

Server's signature

Printed name and title

Server's address

Additional information regarding attempted service, etc.:

Federal Rule of Civil Procedure 45 (c), (d), (e), and (g) (Effective 12/1/13)**(c) Place of Compliance.**

(1) *For a Trial, Hearing, or Deposition.* A subpoena may command a person to attend a trial, hearing, or deposition only as follows:

- (A) within 100 miles of where the person resides, is employed, or regularly transacts business in person; or
- (B) within the state where the person resides, is employed, or regularly transacts business in person, if the person
 - (i) is a party or a party's officer; or
 - (ii) is commanded to attend a trial and would not incur substantial expense.

(2) *For Other Discovery.* A subpoena may command:

- (A) production of documents, electronically stored information, or tangible things at a place within 100 miles of where the person resides, is employed, or regularly transacts business in person; and
- (B) inspection of premises at the premises to be inspected.

(d) Protecting a Person Subject to a Subpoena; Enforcement.

(1) *Avoiding Undue Burden or Expense; Sanctions.* A party or attorney responsible for issuing and serving a subpoena must take reasonable steps to avoid imposing undue burden or expense on a person subject to the subpoena. The court for the district where compliance is required must enforce this duty and impose an appropriate sanction—which may include lost earnings and reasonable attorney's fees—on a party or attorney who fails to comply.

(2) *Command to Produce Materials or Permit Inspection.*

(A) *Appearance Not Required.* A person commanded to produce documents, electronically stored information, or tangible things, or to permit the inspection of premises, need not appear in person at the place of production or inspection unless also commanded to appear for a deposition, hearing, or trial.

(B) *Objections.* A person commanded to produce documents or tangible things or to permit inspection may serve on the party or attorney designated in the subpoena a written objection to inspecting, copying, testing, or sampling any or all of the materials or to inspecting the premises—or to producing electronically stored information in the form or forms requested. The objection must be served before the earlier of the time specified for compliance or 14 days after the subpoena is served. If an objection is made, the following rules apply:

- (i) At any time, on notice to the commanded person, the serving party may move the court for the district where compliance is required for an order compelling production or inspection.
- (ii) These acts may be required only as directed in the order, and the order must protect a person who is neither a party nor a party's officer from significant expense resulting from compliance.

(3) *Quashing or Modifying a Subpoena.*

(A) *When Required.* On timely motion, the court for the district where compliance is required must quash or modify a subpoena that:

- (i) fails to allow a reasonable time to comply;
- (ii) requires a person to comply beyond the geographical limits specified in Rule 45(c);
- (iii) requires disclosure of privileged or other protected matter, if no exception or waiver applies; or
- (iv) subjects a person to undue burden.

(B) *When Permitted.* To protect a person subject to or affected by a subpoena, the court for the district where compliance is required may, on motion, quash or modify the subpoena if it requires:

- (i) disclosing a trade secret or other confidential research, development, or commercial information; or

(ii) disclosing an unretained expert's opinion or information that does not describe specific occurrences in dispute and results from the expert's study that was not requested by a party.

(C) *Specifying Conditions as an Alternative.* In the circumstances described in Rule 45(d)(3)(B), the court may, instead of quashing or modifying a subpoena, order appearance or production under specified conditions if the serving party:

- (i) shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship; and
- (ii) ensures that the subpoenaed person will be reasonably compensated.

(e) Duties in Responding to a Subpoena.

(1) *Producing Documents or Electronically Stored Information.* These procedures apply to producing documents or electronically stored information:

(A) *Documents.* A person responding to a subpoena to produce documents must produce them as they are kept in the ordinary course of business or must organize and label them to correspond to the categories in the demand.

(B) *Form for Producing Electronically Stored Information Not Specified.* If a subpoena does not specify a form for producing electronically stored information, the person responding must produce it in a form or forms in which it is ordinarily maintained or in a reasonably usable form or forms.

(C) *Electronically Stored Information Produced in Only One Form.* The person responding need not produce the same electronically stored information in more than one form.

(D) *Inaccessible Electronically Stored Information.* The person responding need not provide discovery of electronically stored information from sources that the person identifies as not reasonably accessible because of undue burden or cost. On motion to compel discovery or for a protective order, the person responding must show that the information is not reasonably accessible because of undue burden or cost. If that showing is made, the court may nonetheless order discovery from such sources if the requesting party shows good cause, considering the limitations of Rule 26(b)(2)(C). The court may specify conditions for the discovery.

(2) *Claiming Privilege or Protection.*

(A) *Information Withheld.* A person withholding subpoenaed information under a claim that it is privileged or subject to protection as trial-preparation material must:

- (i) expressly make the claim; and
- (ii) describe the nature of the withheld documents, communications, or tangible things in a manner that, without revealing information itself privileged or protected, will enable the parties to assess the claim.

(B) *Information Produced.* If information produced in response to a subpoena is subject to a claim of privilege or of protection as trial-preparation material, the person making the claim may notify any party that received the information of the claim and the basis for it. After being notified, a party must promptly return, sequester, or destroy the specified information and any copies it has; must not use or disclose the information until the claim is resolved; must take reasonable steps to retrieve the information if the party disclosed it before being notified; and may promptly present the information under seal to the court for the district where compliance is required for a determination of the claim. The person who produced the information must preserve the information until the claim is resolved.

(g) *Contempt.*

The court for the district where compliance is required—and also, after a motion is transferred, the issuing court—may hold in contempt a person who, having been served, fails without adequate excuse to obey the subpoena or an order related to it.

BERGER & MONTAGUE, P.C.

107547

REF. #	INVOICE #	INV. DATE	INVOICE AMOUNT	CLIENT
133337	12138 10914	10/09/2014	\$55.46	NEXIUM

THIS CHECK HAS A COLORED BACKGROUND AND CONTAINS MULTIPLE SECURITY FEATURES. SEE BACK FOR DETAILS.

BERGER & MONTAGUE, P.C.

1622 LOCUST STREET
PHILADELPHIA, PA 19103

THE HUNTINGTON NATIONAL BANK

COLUMBUS, OHIO 43216
huntington.com

107547

CHECK NO.

56-1503412

PAY

Fifty Five and 46/100 Dollars

DATE

10/09/2014

AMOUNT

\$55.46

TWO SIGNATURES REQUIRED FOR AMOUNTS OVER \$5000.

TO THE
ORDER
OF

RANBAXY, INC.



VOID AFTER 180 DAYS

⑈ 107547 ⑈ ⑆044000024⑆ 01892603216⑈

Attachment A

Plaintiffs seek testimony from the Keeper of Records regarding business records produced by your company to which you have objected on authenticity, hearsay or “double hearsay” grounds, as stated on the spreadsheet named “Defendants_Objections to Plaintiffs_Revised Exhibit List 10.06.2013xlsx.xlsx” sent by your counsel in this action to plaintiffs on October 6, 2014, a print-out of which is attached as Attachment B.

Plaintiffs seek testimony from the Keeper of Records concerning the authenticity of the documents and whether the document is a business record pursuant to Federal Rule of Evidence 803(6).

Testimony at the location listed on the subpoena will be given via contemporaneous audio/video transmission to the courtroom in Boston, Massachusetts at which trial in this matter will be taking place. If, in lieu of testifying via audio/video transmission, the Keeper of Records will agree to appear voluntarily in the Federal District Court for the District of Massachusetts, where this action is pending, in Boston, Massachusetts to testify, counsel for the company and the Keeper of Records should contact:

Thomas M. Sobol
Hagens Berman Sobol Shapiro LLP
55 Cambridge Parkway, Suite 301 - Cambridge, MA 02142
(617) 475-1950

Attachment B

Pl. Ex.	Description	Date	Exhibits	EndDoc	Additional Notes	REVISED OBJECTION
0001	Settlement Agreement (Ranbaxy)	04/14/2008	AZ-NX-MDL-00000005	AZ-NX-MDL-00000031		
0002	Distribution Agreement (Ranbaxy - Plendil)	04/14/2008	AZ-NX-MDL-00000032	AZ-NX-MDL-00000092		
0003	Distribution Agreement (Ranbaxy - Prilosec)	04/14/2008	AZ-NX-MDL-00000093	AZ-NX-MDL-00000154		
0004	Ballment Agreement	04/14/2008	AZ-NX-MDL-00000155	AZ-NX-MDL-00000160		
0005	Supply Agreement	04/14/2008	AZ-NX-MDL-00000161	AZ-NX-MDL-00000204		
0006	Tolling Agreement	04/14/2008	AZ-NX-MDL-00000205	AZ-NX-MDL-00000248		
0007	Development and Technology Transfer Agreement	06/04/2008	NEX-RBX 3509695	NEX-RBX 3509745		Incomplete
0008	Quality Assurance Agreement (Ohm)	12/15/2008	RAN-ESM 0676926	RAN-ESM 0676972		
0009	Quality Assurance Agreement (Ohm)	01/07/2013	RAN-ESM 0676976	RAN-ESM 0677033		
0020	AstraZeneca project scope document from E. Teneberg to M. Platt. Project Scope for Esomeprazole 2nd source.	10/05/2004	NEX-RBX 3525093	NEX-RBX 3525094		
0027	Ranbaxy spreadsheet, ANDA Portfolio Summary.	12/31/2005	RAN-ESM0096779	RAN-ESM0096790		Hearsay
0028	AstraZeneca document. Minutes of 34th Supply Committee Meeting on 7 Feb 2006 at Alderley Park.	02/07/2006	NEX-RBX 3525080	NEX-RBX 3525084		Incomplete; Relevance; Hearsay
0030	AstraZeneca Supply Committee Agenda Paper. Omeprazole and Esomeprazole sourcing review.	02/07/2006	NEX-RBX 3525109	NEX-RBX 3525112		Hearsay
0032	AstraZeneca Project Closure document from E. Teneberg to R. Alves and S. Fishwick. Project Closure for Esomeprazole API 2nd source.	03/09/2006	NEX-RBX 3525085	NEX-RBX 3525088		Hearsay
0033	Email from S. Labit to K. Guertte with attached Plendil spreadsheets	12/13/2006	NEX-RBX 3485738	NEX-RBX 3485789		Hearsay
0037	Email from J. Todisco to R. Johnson	05/22/2007	RAN-ESM0233747	RAN-ESM0233749		Hearsay; Relevance
0038	Email from J. Dushmukh to J. Pott	07/30/2007	NEX-RBX 00000001	NEX-RBX 00000001		Authenticity; Hearsay
0039	Email from S. Pandit to J. Todisco with attached spreadsheet	08/08/2007	RAN-ESM0231243	RAN-ESM0231279		Relevance; Hearsay
0040	Email from S. Pandit to J. Todisco with attached spreadsheet	08/09/2007	RAN-ESM0232274	RAN-ESM0232440		Relevance; Hearsay
0041	Email from S. Pandit to J. Todisco with attached spreadsheet	08/16/2007	RAN-ESM0232441	RAN-ESM 0232607		Relevance; Hearsay
0042	Email from J. Dushmukh to J. Pott, M. Helfetz and W. Krovatin	08/23/2007	NEX-RBX 00000002	NEX-RBX 00000003		Relevance; Hearsay
0043	Greenstone Ltd. presentation by Bill Kennally, Authorized Generics (AGs) What's Changed? Presented at 8th Annual Generic Drug Summit, Institute for International Research.	09/01/2007	RAN-ESM0173010	RAN-ESM0173035		Authenticity; Double Hearsay; Hearsay
0044	Email from G. Mehrotra to P.P. Nath and L. Ahluwalia with attached presentations	09/21/2007	RAN-ESM0172964	RAN-ESM0173035		Foundation; Hearsay
0045	Email from P. Safir to D. Adams	10/12/2007	NEX-RBX 00000004	NEX-RBX 00000005		Double Hearsay; Hearsay; Relevance
0046	Email from D. Adams to P. Safir with attached letter from Ranbaxy to FDA	10/31/2007	NEX-RBX 00000008	NEX-RBX 00000013		Hearsay; Relevance
0049	Email from J. Dushmukh to J. Pott	11/08/2007	NEX-RBX 3510039	NEX-RBX 3510039		Hearsay
0051	Email from A. Aboltezz to J. Pott	11/16/2007	NEX-RBX 3508565	NEX-RBX 3508567		Double Hearsay; Hearsay; Incomplete
0055	Email from T. Hester to L. Fales with attached draft Settlement Agreement	12/04/2007	NEX-RBX 00000014	NEX-RBX 00000036		

Index	Description	Date	Ref Doc	Exhib	Additional Notes	REVISED OBJECTION
0056	E-mail from J. Pott to A. Aboelezz	12/12/2007	NEX-RBX 3510044	NEX-RBX 3510045		Double Hearsay; Hearsay
0059	E-mail from J. Pott to A. Aboelezz	12/14/2007	RAN-ESM 0248372	RAN-ESM 0248373		Relevance
0060	E-mail from L. Fales to T. Hester with attached draft settlement agreement	12/17/2007	NEX-RBX 0000039	NEX-RBX 0000068		
0062	AstraZeneca document, 2008 US Product Strategic Plan: NEXIUM.	12/18/2007	AZ-NX-MDL-00873061	AZ-NX-MDL-00873088		
0064	E-mail from T. Hester to J. Deshmukh, A. Aboelezz and D. Adams with attached draft Settlement Agreement	01/05/2008	NEX-RBX 0000069	NEX-RBX 0000094		
0067	E-mail from J. Deshmukh to A. Aboelezz	01/08/2008	RAN-ESM 0248367	RAN-ESM 0248369		Hearsay
0073	E-mail from A. Aboelezz to T. Bowman, P. Janson and J. Deshmukh	01/17/2008	NEX-RBX 3510465	NEX-RBX 3510470		Hearsay; Relevance
0074	E-mail from B. Winter to Venkatachalam K. and J. Meehan	01/17/2008	RAN-ESM 0203334	RAN-ESM 0203335		Hearsay
0077	E-mail from P.P. Nath to Venkatachalam K. with attached forecast spreadsheets for Amlodipine + Atorvastatin, Donepezil, Esomeprazole, Memantine, Losartan and Pioglitazone	01/29/2008	RAN-ESM 0203360	RAN-ESM 0203401		
0078	E-mail from M. McCourt to M. Ladha with attachments	01/30/2008	NEX-RBX 3485910	NEX-RBX 3485913		Relevance; Hearsay
0081	E-mail from J. Todisco to Venkatachalam K.	02/05/2008	RAN-ESM 0203418	RAN-ESM 0203418		Hearsay
0084	E-mail from A. Kalra to multiple recipients	03/07/2008	RAN-ESM 022944	RAN-ESM 022945		Authenticity; Hearsay
0085	E-mail from A. Kalra to O. Sethi and P. Gupta with attached Key Country Growth Drivers CAGR 2008-2012 spreadsheet, Value Drivers MMS Feb 2008 presentation, FTF Questions Part II document, FTF Questions document and GCSF Financial Analysis spreadsheet	03/10/2008	RAN-ESM 022974	RAN-ESM 022976	RAN-ESM 022980 - RAN-ESM 022990; RAN-ESM 0223029 - RAN-ESM 0223032; RAN-ESM 0223037 - RAN-ESM 0223041	Authenticity; Double Hearsay; Hearsay
0086	Memo from K. Monday to M. McCourt, Esomeprazole Magnesium 20mg and 40mg Capsules.	03/26/2008	NEX-RBX 3514304	NEX-RBX 3514305		Incomplete; Relevance; Hearsay
0089	E-mail from B. Zimmerman to T. Hester, J. Deshmukh, A. Aboelezz and D. Adams	04/08/2008	NEX-RBX 0000226	NEX-RBX 0000227		Hearsay
0090	E-mail from J. Deshmukh to T. Hester, A. Aboelezz, B. Zimmerman and D. Adams	04/08/2008	NEX-RBX 0000228	NEX-RBX 0000228		Hearsay
0093	E-mail from J. Deshmukh to J. Pott	04/09/2008	NEX-RBX 3508998	NEX-RBX 3508999		Hearsay
0107	E-mail from J. Deshmukh to T. Hester, J. Pott, A. Aboelezz, D. Adams and B. Zimmerman	04/14/2008	NEX-RBX 0000362	NEX-RBX 0000362		Hearsay
0115	Collection of press releases and press reports regarding the AstraZeneca/Ranbaxy Nexium settlement and manufacturing/distribution agreements	04/15/2008	NEX-RBX 3429510	NEX-RBX 3429522		Hearsay; Relevance
						1088 Double Hearsay; Foundation; Hearsay; Unfairly Prejudicial

Item No.	Description	Date	De-Dep	End Doc	Additional Dates	REVISED OBJECTION
0117	E-mail from S. Saffaya to undisclosed recipients	04/16/2008	RAN-ESM00091990	RAN-ESM00091944		Authenticity; Double Hearsay; Foundation; Hearsay; Unfairly Prejudicial
0118	E-mail from A. Kalra to multiple recipients	04/16/2008	RAN-ESM0202989	RAN-ESM0202990		Foundation; Hearsay; Incomplete
0120	AstraZeneca minutes. Esomeprazole: Initial meeting on activities relating to outsourcing of esomeprazole (API), 23 April 2008.	04/23/2008	NEX-RBX 3525374	NEX-RBX 3525376		Hearsay
0124	Letter from AstraZeneca counsel to the FTC	05/02/2008	AZ-NX-MDL-00968287	AZ-NX-MDL-00968288		Hearsay; Prejudice
0127	E-mail from T. Eswar to V. Madan with attached Agenda	05/06/2008	RAN-ESM029361	RAN-ESM029363		
0139	AstraZeneca memo. Minutes and Action Items from AZ/Ohm Meeting, May 6, 2008.	05/12/2008	NEX-RBX 3513636	NEX-RBX 3513638		Double Hearsay; Hearsay
0159	E-mail from P. Rajan to S. Pandit with attached Esomeprazole Forecast spreadsheet	07/03/2008	RAN-ESM0188701	RAN-ESM0188725		Relevance; Hearsay
0161	E-mail from S. Rajan to S. Pandit with attached Esomeprazole Capsules DR Executive Summary	07/03/2008	RAN-ESM0188737	RAN-ESM0188762		Authenticity; Hearsay; Relevance
0162	Civil Investigative Demand to Ranbaxy, FTC File No. 0810171	07/03/2008	RAN-ESM0248120	RAN-ESM0248138		Authenticity; Hearsay; Unfairly Prejudicial
0165	Transcript of Investigational Hearing, Jeffrey A. Pott, FTC File No. 0810171	07/23/2008	AZ-NX-MDL-00968317	AZ-NX-MDL-00968411		Double Hearsay; Hearsay; Improper Exhibit (deposition transcript); Unfairly Prejudicial
0167	Transcript of Investigational Hearing, Jay Deshmukh, FTC File No. 0810171	08/28/2008	RAN-ESM 0248233	RAN-ESM 0248286		Hearsay; Improper Exhibit (deposition transcript)
0168	E-mail from J. Todisco to G. Mehrotra, L. Ahluwalia and Venkatachalam K. with attached spreadsheets	01/08/2009	RAN-ESM 0488131	RAN-ESM 0488222		
0169	E-mail from A. Jain to J. Todisco with attached New Products 2009-2011 spreadsheet	01/10/2009	RAN-ESM 0468752	RAN-ESM 0468758	RAN-ESM 0468764 - RAN-ESM 0468771	Hearsay; Relevance
0170	E-mail from L. Ahluwalia to A. Jain and J. Todisco	01/11/2009	RAN-ESM 0438757	RAN-ESM 0438769		Hearsay; Incomplete; Relevance
0175	Response to Civil Investigative Demand Issued by the Federal Trade Commission to Ranbaxy on July 3, 2008 in File No. 0810171	04/15/2009	RAN-ESM0248153	RAN-ESM0248191		Hearsay; Relevance
0176	E-mail from Ranbaxy counsel to FTC with attached letter, Supplemental Responses to Interrogatories, and Attachment C	05/04/2009	RAN-ESM0248192	RAN-ESM0248199		Unfairly Prejudicial; Hearsay
0177	AstraZeneca's Responses to Civil Investigative Demand Interrogatory Specifications, FTC File No. 0810171	05/29/2009	AZ-NX-MDL-00003622	AZ-NX-MDL-00003637		Unfairly Prejudicial; Hearsay
0181	AstraZeneca's Supplemental Response to Civil Investigative Demand Interrogatory Specification Number 11, FTC File No. 0810171	09/03/2009	AZ-NX-MDL-00003638	AZ-NX-MDL-00003639		Hearsay; Unfairly Prejudicial
0182	E-mail from J. Todisco to C. Capriello with attached Ranbaxy US Business Overview presentation	09/15/2009	RAN-ESM 0469012	RAN-ESM 0469083		Double Hearsay; Hearsay; Unfairly Prejudicial
0192	Minutes from AZ Steering Committee Meeting on February 10, 2010	03/15/2010	RAN-ESM 0297861	RAN-ESM 0297864		Misleading; Relevance; Hearsay
						Incomplete; Relevance; Hearsay

File #	Description	Date	Page Doc	Exhibit Doc	Additional Dates	Revised Object
0195	E-mail - Ranbaxy E-mail string re: AZ/Ranbaxy and OHM accounts	05/21/2010	RAN-ESM 0296319	RAN-ESM 0296325		Authenticity; Hearsay; Relevance
0215	E-mail from R. Riccobon to S. Sarada	07/11/2011	RAN-ESM 0308401	RAN-ESM 0308402		Authenticity; Hearsay; Relevance
0216	AstraZeneca - Ohm Laboratories - Sales & Operations Planning Meeting Agenda	08/16/2011	RAN-ESM 0313413	RAN-ESM 0313428		Authenticity; Hearsay; Relevance
0217	E-mail from FTC to Ranbaxy counsel with attached Second Civil Investigative Demand to Ranbaxy, FTC File No. 0810171	08/23/2011	RAN-ESM0248200	RAN-ESM0248212		Authenticity; Hearsay; Relevance
0218	Transcript of Investigational hearing, Richard Barker, FTC File No. 0810171	09/01/2011	AZ-NX-MDL-00968186	AZ-NX-MDL-00968235		Authenticity; Hearsay; Unfairly Prejudicial
0219	E-mail from Pandi to Blank RE: Esomeprazole (9.6.11)	09/12/2011	RAN-ESM 0457647	RAN-ESM 0457647		Double Hearsay; Hearsay; Unfairly Prejudicial
0220	Transcript of Investigational hearing, David Pitman Snow, FTC File No. 081071	09/21/2011	AZ-NX-MDL-00968236	AZ-NX-MDL-00968285		Authenticity; Hearsay; Relevance
0222	Letter from AstraZeneca counsel to FTC with attached AstraZeneca's Responses to Second Civil Investigative Demand Interrogatory Specification, FTC File No. 0810171	09/30/2011	AZ-NX-MDL-00003645	AZ-NX-MDL-00003659		Double Hearsay; Hearsay; Unfairly Prejudicial
0224	Response to Second Civil Investigative Demand Issued by the Federal Trade Commission to Ranbaxy on August 19, 2011, FTC File No. 0810171	09/30/2011	RAN-ESM0248218	RAN-ESM0248226		Hearsay; Incomplete; Unfairly Prejudicial
0229	Agenda for AZ Ohm Laboratories Sales & Operations Planning Meeting; 2012 January Forecasts for Capsules from Ohm to Astra USA; 2011 December API Forecast from Ohm to Astra USA; Capsule and API Purchase Order lists; API Shipment Delivery Updates	01/17/2012	RAN-ESM 0305682	RAN-ESM 0305699		Unfairly Prejudicial; Hearsay
0230	Agenda for AZ Ohm Laboratories Sales & Operations Planning Meeting; 2012 February Forecasts for Capsules from Ohm to Astra USA; 2012 January API Forecast from Ohm to Astra USA; Capsule and API Purchase Order lists; Shipment Delivery Updates; E-mail from J. McAbee to P.P. Nath and R. Jain with attached AstraZeneca Ohm S&OP Meeting packet	02/14/2012	RAN-ESM 0318200	RAN-ESM 0318223		Incomplete; Hearsay; Relevance
0232	Ranbaxy spreadsheet: Esomeprazole Forecast - Teva Loss.	03/01/2012	RAN-ESM0234301	RAN-ESM0234449		Hearsay; Relevance
0234	E-mail from J. McAbee to P.P. Nath and R. Jain with attached AstraZeneca Ohm S&OP Meeting packet	03/09/2012	RAN-ESM 0318151	RAN-ESM 0318174		Incomplete; Hearsay; Relevance
0236	E-mail from R. Jain to multiple recipients with attached AstraZeneca Ohm S&OP Meeting packet	04/16/2012	RAN-ESM 025791.4	RAN-ESM 0257936		Hearsay; Relevance
						Hearsay; Relevance

Case No.	Description	Date	DepDoc	EndDoc	Additional Dates	REVIEWED/OBJECTED
0237	E-mail from R. Jain to multiple recipients with attached AstraZeneca Ohm S&OP Meeting packet	05/14/2012	RAN-ESM 0255975	RAN-ESM 0255998		
0238	E-mail from J. McAbee to P.P. Nath and R. Jain with attached AstraZeneca Ohm S&OP Meeting packet	05/12/2012	RAN-ESM 0301034	RAN-ESM 0301056		Hearsay, Relevance
0240	E-mail from R. Jain to multiple recipients with attached AstraZeneca Ohm S&OP Meeting packet	07/17/2012	RAN-ESM 0255913	RAN-ESM 0255935		Hearsay, Relevance
0244	AstraZeneca - Ohm Laboratories - Sales & Operations Planning Meeting Agenda	08/15/2012	RAN-ESM 0255225	RAN-ESM 0255248		Hearsay, Relevance
0245	AstraZeneca - Ohm Laboratories - Sales & Operations Planning Meeting Agenda	09/19/2012	RAN-ESM 0254369	RAN-ESM 0254391		Incomplete; Hearsay, Relevance
0246	E-mail from R. Jain to multiple recipients with attached AstraZeneca Ohm S&OP Meeting packet	10/16/2012	RAN-ESM 0253962	RAN-ESM 0253985		Incomplete; Hearsay, Relevance
0247	AstraZeneca - Ohm Laboratories - Sales & Operations Planning Meeting Agenda	11/14/2012	RAN-ESM 0253588	RAN-ESM 0253611		Hearsay, Relevance
0248	AstraZeneca/Ohm Laboratories - Sales & Operations Planning Meeting Agenda	12/12/2012	RAN-ESM 0253488	RAN-ESM 0253510		Incomplete; Hearsay, Relevance
0249	AstraZeneca - Ohm Laboratories - Sales & Operations Planning Meeting Agenda	01/16/2013	RAN-ESM 0263897	RAN-ESM 0263919		Incomplete; Hearsay, Relevance
0252	AstraZeneca/Ohm Laboratories - Sales & Operations Planning Meeting Agenda	03/20/2013	RAN-ESM 0286596	RAN-ESM 0286616		Incomplete; Hearsay, Relevance
0253	E-mail from J. McAbee to P.P. Nath and R. Jain with attached AstraZeneca Ohm S&OP Meeting packet	04/15/2013	RAN-ESM 0286508	RAN-ESM 0286529		Incomplete; Hearsay, Relevance
0254	Settlement Agreement (Teva)	01/06/2010	AZ-NX-MDL-00000254	AZ-NX-MDL-00000285		
0255	Settlement Agreement (Teva - Pliosec)	01/06/2010	AZ-NX-MDL-00000296	AZ-NX-MDL-00000326		Hearsay, Relevance
0256	Strategic Alliance Agreement between Impax Laboratories, Inc. and Teva Pharmaceuticals Curacao N.V.	10/08/2003	Teva-ESO-098043	Teva-ESO-098047		
0261	E-mail from S. Julie to M. Heifetz with attached financial information	04/18/2006	Teva-ESO-023577	Teva-ESO-023578		Relevance
0271	Transcript of proceedings, No. 98-cv-08094 and No. M-21-81 (S.D.N.Y.)	10/30/2008	AZ-NX-MDL-01015835	AZ-NX-MDL-01015844		Hearsay; Incomplete; Relevance
0273	Letter from AstraZeneca counsel to Teva counsel with attached Astra's Responses to Defendant Teva's First Set of Interrogatories (Nos. 1-2) to Plaintiffs, No. 05-cv-00621 and No. M-21-81 (S.D.N.Y.)	12/02/2008	AZ-NX-MDL-01016193	AZ-NX-MDL-01016251		Hearsay
0274	E-mail from O. Yart to S. Julie	12/04/2008	Teva-ESO-026869	Teva-ESO-026869		Hearsay
0275	Transcript of proceedings, No. 08-cv-02185 and No. 08-cv-02496 (D.N.J.)	12/17/2008	Teva-ESO-107763	Teva-ESO-107703		Hearsay Foundation; Relevance

Case No.	Description	Date	Page Doc	End Doc	Add'l Dates	REVISED/OBJECT
0278	Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc.'s Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-13) Related to Damages, Willful Infringement and Exceptional Case Determinations, No. 05-cv-00621 (S.D.N.Y.)	01/21/2009	AZ-NX-MDL-01016883	AZ-NX-MDL-01016904		
0279	Letter from AstraZeneca counsel to Teva counsel with attached Astra's Responses to Defendant Teva's Second Set of Interrogatories (Nos. 3-17) to Plaintiffs, No. 05-cv-00621 and No. M-21-81 (S.D.N.Y.)	01/23/2009	AZ-NX-MDL-01016958	AZ-NX-MDL-01016975		Hearsay
0280	Letter from John M. Griem, Jr., to Special Master Gale R. Peterson re: In re Omeprazole Patent Litigation, M-21-81 - AstraZeneca's Opposition to Teva's Motion to Compel Plaintiffs to Provide Documents and Information Relating to Damages. Attached Exhibit A is a letter from Mr. Griem to Ashley Gray dated 04/01/2009. Attached Exhibit B is a Declaration of John M. Griem, Jr., dated 04/15/2009.	04/15/2009	Teva-ESO-112721	Teva-ESO-112742		Hearsay
0282	Transcript of conference call hearing, No. M-21-81 (S.D.N.Y.)	05/27/2009	AZ-NX-MDL-01017668	AZ-NX-MDL-01017821		Relevance; Unfairly Prejudicial
0283	AstraZeneca's Responses to Defendant Teva's Third Set of Interrogatories (Nos. 18-20) to Plaintiffs, No. 05-cv-00621 (S.D.N.Y.)	05/28/2009	AZ-NX-MDL-01017822	AZ-NX-MDL-01017853		Hearsay; Relevance; Unfairly Prejudicial
0284	Transcript of conference call hearing, No. 05-cv-00621 and No. M-21-81 (S.D.N.Y.)	06/19/2009	AZ-NX-MDL-01017951	AZ-NX-MDL-01018078		Hearsay; Relevance; Unfairly Prejudicial
0285	E-mail from T. Hester to D. Stark with attached draft Settlement Agreements	08/26/2009	AZ-NX-MDL-00002508	AZ-NX-MDL-00002556		Double Hearsay; Hearsay; Unfairly Prejudicial
0286	E-mail from K. Kean to M. Helfetz with attached draft Settlement Agreements	09/09/2009	AZ-NX-MDL-00001753	AZ-NX-MDL-00001753	AZ-NX-MDL-00000693 - AZ-NX-MDL-00000797	Double Hearsay; Hearsay
0287	E-mail from T. Hester, Timothy to multiple recipients with attached revised draft settlement agreements	10/07/2009	AZ-NX-MDL-00002106	AZ-NX-MDL-00002106		Hearsay; Incomplete
0289	E-mail from K. Kean to T. Hester	11/13/2009	AZ-NX-MDL-00001859	AZ-NX-MDL-00001859		Hearsay; Incomplete
0290	E-mail from T. Hester to K. Kean	12/01/2009	AZ-NX-MDL-00001984	AZ-NX-MDL-00001984		Hearsay; Incomplete
0292	E-mail from T. Hester to K. Kean and S. Julie	12/08/2009	AZ-NX-MDL-00002216	AZ-NX-MDL-00002216		Hearsay; Incomplete
0293	E-mail from K. Kean to T. Hester	12/15/2009	AZ-NX-MDL-00002341	AZ-NX-MDL-00002342		Hearsay; Incomplete
0294	E-mail from T. Hester to K. Kean	12/17/2009	AZ-NX-MDL-00002557	AZ-NX-MDL-00002557		Hearsay; Incomplete
0295	E-mail from Taft, Kingley to Hester, Timothy RE: Omeprazole and Esomeprazole Settlement Agreements, Subject to Federal Rule of Evidence 408 attaching Settlement Agreement (esomeprazole).DOC	12/19/2009	AZ-NX-MDL-00002469	AZ-NX-MDL-00002470		Hearsay; Incomplete

P. Ex.	Description	Date	Exhibit	Revised/Objection	Additional Notes
0297	E-mail from Tasi, Kingsley to Hester, Timothy regarding Omeprazole and Esomeprazole Settlement Agreements and PR attaching PR Redline.doc; TEVA AZ PR draft 04012010.doc; Execution Version Omeprazole_Prilosec Agreement.DOC; Execution Version Esomeprazole_Nexium Agreement.DOC; Redline - omeprazole.doc; Redline - esomeprazole.doc	01/05/2010	AZ-NX-MDL-00002682		
0299	Nexium (esomeprazole) Product Brief	01/01/2011	AZ-NX-MDL-00084551		Hearsay; Incomplete
0300	Settlement Agreement (DRL)	01/18/2011	AZ-NX-MDL-00000331		Hearsay
0302	E-mail from A. Miller to J. Rhlinger with attachments	12/23/2008	DRLMDL 180154		
0312	E-mail from Ajay Singh to Lee Banks and Anjum Swaroop re Fw: Meeting and thank you	07/22/2010	DRLMDL 173252		Authenticity; Hearsay; Relevance; Collateral Issue; Unfairly Prejudicial
0324	E-mail from A. Singh to M. Heifetz with attached Brain-storming sheet	09/20/2010	AZ-NX-MDL-00003394		Relevance; Unfairly Prejudicial; Relevance; (Accolite)
0325	E-mail from M. Heifetz to A. Singh	09/21/2010	AZ-NX-MDL-00003396		Hearsay; Relevance; Unfairly Prejudicial; (Accolite)
0327	E-mail from A. Singh to A. Miller, A. Patel and L. Banks	10/13/2010	DRLMDL 263091		Hearsay; Relevance; Unfairly Prejudicial; (Accolite)
0346	E-mail from A. Singh to A. Mukherjee	12/30/2010	DRLMDL 172348		Authenticity; Hearsay
0347	E-mail from Heifetz, Marcus to Ajay Singh regarding Basic overview of proposal to settle litigations	12/31/2010	AZ-NX-MDL-00001572		Unfairly Prejudicial; Relevance; (Accolite)
0348	E-mail from A. Singh to M. Heifetz	01/01/2011	AZ-NX-MDL-00002809		Hearsay; Unfairly Prejudicial; Relevance; (Accolite)
0349	E-mail from T. Hester to A. Singh and L. Banks	01/03/2011	AZ-NX-MDL-00001450		Unfairly Prejudicial; Relevance; (Accolite)
0350	E-mail from Hester, Timothy to Andrew Miller regarding Nexium/Accolite attaching AZ.DRL Nexium agreement.DOC; CV_Cmparison #3846193v3 DC - AZ.DRL Nexium agreement January 3-#3846193v4_DC - AZ.DRL Nexium agreement.doc	01/05/2011	AZ-NX-MDL-00001361		Hearsay; Unfairly Prejudicial; Relevance; (Accolite)
0354	E-mail from Hester, Timothy to Andrew Miller regarding Nexium/Accolite with copy Draft Settlement Agreement - Draft - between AZ, KBI, Merck and DRL	01/05/2011	DRLMDL 171402		Hearsay; Unfairly Prejudicial; Relevance; (Accolite)
0357	E-mail from Ajay Singh to multiple recipients re Esomeprazole Settlement Update	01/06/2011	DRLMDL 172884		Authenticity; Hearsay; Unfairly Prejudicial; Relevance; (Accolite)
0364	E-mail from Hester, Timothy to Andrew Miller regarding Execution Versions of Settlement Agreements attaching AZ.DRL Accolite agreement.DOC; AZ.DRL Nexium Agreement.DOC; AZ.DRL press release.DOC	01/17/2011	AZ-NX-MDL-00001486		Unfairly Prejudicial; Relevance; (Accolite)
					Hearsay; Incomplete; Unfairly Prejudicial; Relevance; (Accolite)

Case#	Description	Date	Revised Doc	End Doc	Additional Pages	Revised Objection
0366	E-mail from Hester, Timothy to Andrew Miller regarding Execution Versions of Settlement Agreements with copies of Settlement Agreement between AZ, KBI, Merck and DRL	01/17/2011	DRLMDL 171549	DRLMDL 171597		
0367	E-mail from A. Singh to A. Mukherjee	01/17/2011	DRLMDL 234405	DRLMDL 234407		Authenticity; Hearsay; Unfairly Prejudicial; Relevance; (Accolite)
0372	E-mail from A. Miller to P. Schaefer with attached Settlement Agreements	01/25/2011	DRLMDL 171640	DRLMDL 171692		Hearsay; Unfairly Prejudicial; Relevance; (Accolite)
0376	Settlement Agreement (Sandoz)	05/11/2011	AZ-NX-MDL-00000383	AZ-NX-MDL-00000416		Authenticity; Hearsay; Unfairly Prejudicial; Relevance; (Accolite)
0377	Settlement Agreement (Lupin)	01/10/2012	AZ-NX-MDL-00000417	AZ-NX-MDL-00000455		
0378	Settlement Agreement (Hetero)	04/10/2012	AZ-NX-MDL-00000456	AZ-NX-MDL-00000485		
0379	Settlement Agreement (Torrent)	05/01/2012	AZ-NX-MDL-00000490	AZ-NX-MDL-00000524		
0380	AstraZeneca document. Product: Esomeprazole, Request for Proposal to Suppliers.	05/16/2005	AZ-NX-MDL-00773374	AZ-NX-MDL-00773383		
0382	E-mail from C. Trulsson to R. Barker and G. Backlund	08/16/2007	NEX-RBX 3514361	NEX-RBX 3514365		Hearsay
0384	Presentation from AZ entitled "Genesis" with information re: Formulation/Packaging Strategy and High Level Timeline (redactions)	08/17/2007	NEX-RBX 3505851	NEX-RBX 3505857		Double Hearsay; Hearsay
0385	AstraZeneca document. Genesis--- Generic Landscape Talking Points.	08/21/2007	NEX-RBX 3514334	NEX-RBX 3514334		Hearsay
0386	E-mail from Myers, Mary Ellen to Barker, Richard S; McCarthy, John A. (CBL) regarding Genesis Template attaching Genesis TalkingPoints.doc	08/22/2007	NEX-RBX 3514332	NEX-RBX 3514333		Authenticity; Hearsay
0387	E-mail from S. Rothwein to R. Barker	08/25/2007	NEX-RBX 3514366	NEX-RBX 3514366		Hearsay; Incomplete
0388	E-mail from Barker, Richard S. to McCarthy, John A. (CBL) regarding Genesis	09/10/2007	NEX-RBX 3503198	NEX-RBX 3503198		Hearsay
0389	E-mail from Richard S. Barker to John A. McCarthy, Marion McCourt re: Genesis Info	09/17/2007	NEX-RBX 3525168	NEX-RBX 3525168		Double Hearsay; Hearsay
0392	E-mail from Barker, Richard S. to multiple recipients regarding Genesis Volumes	10/24/2007	NEX-RBX 3514367	NEX-RBX 3514367		Hearsay; Incomplete
0395	E-mail from Richard S. Barker to Kathy Monday, Stephen Macrides with CC to Eleanor Lorenc RE: Nexlum AG Consent (redactions)	10/29/2007	NEX-RBX 3514399	NEX-RBX 3514400		Hearsay
0396	E-mail from R. Barker to K. Monday and S. Macrides	10/29/2007	NEX-RBX 3514401	NEX-RBX 3514403		Double Hearsay; Hearsay
0397	AstraZeneca presentation. Potential NEXLUM AG	11/07/2007	AZ-NX-MDL-01243697	AZ-NX-MDL-01243706		Double Hearsay; Hearsay
0398	E-mail from Brazzo, John P. to McCourt, Marion, McCarthy, John A. (CBL) regarding Privileged and Confidential - Attorney Work Product - Final Genesis Slide Deck for Merck Discussion attaching Genesis - MerckFinal.ppt	11/07/2007	NEX-RBX 3505858	NEX-RBX 3505859		Hearsay
0399	E-mail from J. McCarthy, R. Barker, J. Brazzo and M. McCourt	11/08/2007	NEX-RBX 3505870	NEX-RBX 3505873		Hearsay; Incomplete
						Hearsay

Case No.	Description	Date	Begin Doc	End Doc	Additional Dates	Revised Objection
0400	AstraZeneca presentation, Potential NEXIUM AG Overview, November 12, 2007	11/12/2007	NEX-RBX 3456119	NEX-RBX 3456128		Cumulative; Hearsay; Unfairly Prejudicial
0401	Memo from Tim Lawes to Jerker Sandburg and Rick Barker regarding Establish Generic Esomeprazole Mg with attached Capsugel Color Code - 05.377; Capsugel Ink Code - 1014; Print	11/13/2007	NEX-RBX 3515016	NEX-RBX 3515025		Double Hearsay; Hearsay
0402	E-mail from J. Brazzo to multiple recipients with attached Project Genesis Slide - Financials/Forecast - Page 7 of Slide Deck	11/16/2007	AZ-NX-MDL-01243691	AZ-NX-MDL-01243692		Hearsay; Unfairly Prejudicial
0403	Letter from AstraZeneca to KBI-E, Inc. c/o Merck & Co., Inc. providing information regarding discussions of initializing with third parties with respect to distributing an authorized generic version of perprazole (esomeprazole magnesium). AstraZeneca presentation, Genesis Forecast.	11/16/2007	NEX-RBX 3505876	NEX-RBX 3505878		Hearsay
0404	AstraZeneca presentation, Genesis Forecast.	11/20/2007	AZ-NX-MDL-01015763	AZ-NX-MDL-01015766		Hearsay
0405	AstraZeneca presentation, Genesis Forecast.	11/20/2007	AZ-NX-MDL-01243693	AZ-NX-MDL-01243696		Hearsay
0407	E-mail from R. Barker to K. Lundgren-Harikainen, C. Trulsson and P. Pican with attached Potential Nexium AG Overview	11/27/2007	NEX-RBX 3514442	NEX-RBX 3514453		Hearsay
0408	E-mail from R. Barker to K. Monday	12/04/2007	NEX-RBX 3514456	NEX-RBX 3514456		Cumulative; Double Hearsay; Hearsay
0409	E-mail from Barker, Richard S. to Monday, Kathy regarding Genesis	12/05/2007	NEX-RBX 3514336	NEX-RBX 3514337		Cumulative; Double Hearsay; Hearsay
0410	E-mail from K. Monday to R. Barker	12/19/2007	NEX-RBX 3514460	NEX-RBX 3514464		Double Hearsay; Hearsay
0413	AstraZeneca presentation, Nexium Plan B - Working Session, Scenario Review and Discussion.	04/07/2008	NEX-RBX 3505840	NEX-RBX 3505850		Double Hearsay; Hearsay
0414	E-mail from R. Barker to M. McCourt and J. McCarthy	04/14/2008	NEX-RBX 3505881	NEX-RBX 3505881		Hearsay
0415	E-mail from R. Barker to M. McCourt and J. McCarthy	05/12/2008	NEX-RBX 3514306	NEX-RBX 3514306		Hearsay
0416	E-mail from R. Barker to L. Urban	05/16/2008	NEX-RBX 3514307	NEX-RBX 3514307		Double Hearsay; Hearsay
0417	E-mail from M. McCourt to R. Fante	07/29/2008	AZ-NX-MDL-00864316	AZ-NX-MDL-00864317		Hearsay
0418	E-mail from N. Lewis to R. Barker	09/05/2008	AZ-NX-MDL-01020593	AZ-NX-MDL-01020593		Hearsay; Double Hearsay
0421	E-mail from K. Singh to J. Tremayne	12/17/2008	AZ-NX-MDL-00911971	AZ-NX-MDL-00911971		Hearsay; Incomplete
0423	E-mail from B. Sverius to J. Brazzo	01/21/2009	AZ-NX-MDL-00913116	AZ-NX-MDL-00913119		Hearsay
0424	E-mail from F. Rascagneres to R. Barker and M. Olsson with attached Nexium Scenario Volume Summaries spreadsheet	03/19/2009	AZ-NX-MDL-00911218	AZ-NX-MDL-00911219		Hearsay
0425	E-mail from R. Barker to A. GrAagaard	03/03/2010	AZ-NX-MDL-00930861	AZ-NX-MDL-00930862		Hearsay
0428	E-mail from R. Barker to S. Macrides	05/04/2010	AZ-NX-MDL-00966153	AZ-NX-MDL-00966155		Foundation; Hearsay
0429	E-mail from S. Macrides to R. Barker	05/10/2010	AZ-NX-MDL-00943390	AZ-NX-MDL-00943393		Double Hearsay; Hearsay
0430	Presentation; Branded and Generic Threats to Nexium, March 31, 2011	03/31/2011	AZ-NX-MDL-00830356	AZ-NX-MDL-00830356		Hearsay; Double Hearsay
0431	E-mail from S. Macrides to M. Crawford, K. Monday and R. Stellan	09/09/2011	AZ-NX-MDL-00949435	AZ-NX-MDL-00949436		Double Hearsay; Relevance; Misleading; Unfairly Prejudicial
						Hearsay; Misleading; Relevance

Ex. No.	Description	Date	Deposited	End Date	Additional Bates	Revised Objection
0451	Strategic Alliance Agreement between Teva Pharmaceuticals Curacao N.V. and Impax Laboratories, Inc.	06/26/2001	Teva-ESO-098048	Teva-ESO-098086		
0452	IMPAX press release. IMPAX receives FDA approval for omeprazole, a generic version of Prilosec.	11/11/2002	[no bates]			Authenticity; Incomplete
0453	IMPAX press release. IMPAX and Teva launch omeprazole delayed release capsules 20mg.	09/08/2004	[no bates]			
0454	Complaint and Summons, Dkt. 1, No. 05-cv-00621 (S.D.N.Y.)	01/14/2005	Teva-ESO-025009	Teva-ESO-025051		Hearsay
0455	Teva press release. Teva completes acquisition of IVAX.	01/26/2006	[no bates]			Hearsay; Incomplete
0456	Letter from Teva counsel to PriceWaterhouseCoopers. Redlined.	03/08/2006	Teva-ESO-090325	Teva-ESO-090331		Authenticity; Incomplete
0457	IMPAX press release. IMPAX announces decision on generic Prilosec® litigation.	06/01/2007	[no bates]			
0458	Wall Street Journal article. AstraZeneca settles Ranbaxy patent suit.	04/16/2008	[no bates]			
0459	Special Master's Interim Order on Proposed Protective Order, No. 05-cv-00621 (S.D.N.Y.)	03/16/2009	AZ-NX-MDL-01017448	AZ-NX-MDL-01017486		Authenticity; Double Hearsay; Hearsay
0460	Settlement Agreement (Teva - Prilosec). Executed by Teva/Impax only.	01/06/2010	AZ-NX-MDL-00001072	AZ-NX-MDL-00001098		Hearsay; Relevance
0461	Settlement Agreement (DRL). Draft.	01/15/2011	AZ-NX-MDL-00001596	AZ-NX-MDL-00001662		Hearsay; Incomplete
0463	Ranbaxy press release. Ranbaxy and AstraZeneca reach agreement in esomeprazole patent litigation.	undated	[no bates]			
0465	Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc.'s Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-8) Related to Teva's Relationship with Impax, No. 05-cv-00621 (S.D.N.Y.)	12/24/2008	AZ-NX-MDL-01016544	AZ-NX-MDL-01016574		Authenticity; Double Hearsay; Hearsay
0467	USIS Investment Research report. Ranbaxy.	04/15/2008	RAN-ESM0202999	RAN-ESM0203008		Hearsay
0468	E-mail from A. Paulina to J. Berlinska	01/20/2010	Teva-ESO-039266	Teva-ESO-039266		Hearsay; Relevance
0469	Teva Pharmaceutical Industries Limited, Form 6-K	11/07/2008	[no bates]			Relevance
0470	Letter from AstraZeneca counsel to FTC	09/03/2009	AZ-NX-MDL-00003640	AZ-NX-MDL-00003642		Relevance
0471	Letter from AstraZeneca counsel to FTC with attached Appendix	10/11/2013	AZ-NX-MDL-01270564	AZ-NX-MDL-01270568		Hearsay; Unfairly Prejudicial
0472	Defendants Teva Pharmaceuticals' Brief in Support of Their Motion to Lift Stay of Proceedings, Dkt. 29, No. 05-cv-00621 (S.D.N.Y.)	02/21/2006	[no bates]			Hearsay; Unfairly Prejudicial
0473	Brainstorming Sheet and e-mail from Mr. Heller to A. Singh	09/22/2010	AZ-NX-MDL-00003395	AZ-NX-MDL-00003398		Hearsay
0474	Rule 1006 Summary of Ranbaxy Agreement-Related Exhibits	undated	[no bates]			Hearsay; Relevance; Unfairly Prejudicial (Accolite) Authenticity; Cumulative; Double Hearsay; Hearsay; Incomplete; Misleading; Not a proper summary under Rule 1006; Unfairly Prejudicial

Exhibit	Description	Date	Deposited	ERDOC	Additional Notes	REVISED OBJECTION
0475	Rule 1006 Summary of Teva Agreement-Related Exhibits	undated	[no bates]			Authenticity; Cumulative; Double Hearsay; Hearsay; Not a proper summary under Rule 1006; Unfairly Prejudicial
0476	Rule 1006 Summary of DRL Agreement-Related Exhibits	undated	[no bates]			Authenticity; Cumulative; Double Hearsay; Hearsay; Not a proper summary under Rule 1006; Unfairly Prejudicial
0478	Invoices to AstraZeneca for Ranbaxy Nexium capsules supply	undated	AZ-NX-MDL-01243590	AZ-NX-MDL-01243685		Hearsay
0479	AstraZeneca presentation, Potential NEXLUMA® AG Overview.	11/07/2008	NEX-RBX 3505860	NEX-RBX 3505869		Hearsay
0480	E-mail from G. Backlund to R. Barker	08/15/2007	NEX-RBX 3514354	NEX-RBX 3514356		Hearsay
0481	E-mail from B. Viscusi to R. Barker with attached presentation	02/25/2008	NEX-RBX 3514368	NEX-RBX 3514375		Hearsay
0482	Dr. Reddy's Q2 FY11 Financial Result Release	01/25/2011	AZ-NX-MDL-00003399	AZ-NX-MDL-00003402		Authenticity; Double Hearsay; Hearsay; Relevance, Unfairly Prejudicial (Accolade)
0483	Attachment to e-mail from T. Hester to A. Singh and L. Banks (draft Nexium settlement agreement)	01/03/2011	AZ-NX-MDL-00001431	AZ-NX-MDL-00001463		
0485	E-mail from D. Stark to S. Julie	08/04/2009	Teva-ESO-023584	Teva-ESO-023587		Authenticity; Hearsay
0486	E-mail from S. Julie to P. Jeffrey	01/08/2010	Teva-ESO-023674	Teva-ESO-023676		Authenticity; Hearsay; Incomplete
0501	File wrapper for United States Patent Application Serial No. 06/854,739 ('974 patent)	04/21/1986	DPCP-Patent-00000001	DPCP-Patent-00000506		
0502	File wrapper for United States Patent Application Serial No. 07/040,490 ('730 patent)	04/20/1987	DPCP-Patent-00006619	DPCP-Patent-00007059		
0503	File wrapper for United States Patent Application Serial No. 07/040,491 ('505 patent)	04/20/1987	DPCP-Patent-00005007	DPCP-Patent-00006618		
0504	File wrapper for United States Patent Application Serial No. 08/313,036 ('960 patent)	09/27/1994	DPCP-Patent-0000760	DPCP-Patent-0000957		
0505	File wrapper for United States Patent Application Serial No. 08/313,342 ('424 patent)	09/27/1994	DPCP-Patent-00009558	DPCP-Patent-0001218		
0506	File wrapper for United States Patent Application Serial No. 08/376,512 ('504 patent)	01/23/1995	DPCP-Patent-0001219	DPCP-Patent-0001675		
0507	Amendment and Response from file wrapper for United States Patent Application Serial No. 08/376,512 ('504 patent)	02/12/1997	DPCP-Patent-0001399	DPCP-Patent-0001412		Incomplete
0508	Declaration of Andersson from file wrapper for United States Patent Application Serial No. 08/376,512	02/12/1997	DPCP-Patent-0001416	DPCP-Patent-0001438		
0509	File wrapper for United States Patent Application Serial No. 08/492,087 ('789 patent)	07/03/1995	DPCP-Patent-0004245	DPCP-Patent-0004547		
0510	File wrapper for United States Patent Application Serial No. 08/833,962 ('192 patent)	04/11/1997	DPCP-Patent-0001676	DPCP-Patent-0002017		
0511	File wrapper for United States Patent Application Serial No. 09/077,719 ('085 patent)	06/08/1998	DPCP-Patent-0002018	DPCP-Patent-0002219		
0512	File wrapper for United States Patent Application Serial No. 09/169,231 ('213 patent)	10/09/1998	DPCP-Patent-0002220	DPCP-Patent-0002374		
0514	Declaration of Tommy Andersson from file wrapper for United States Patent Application Serial No. 09/187,277	02/23/2000	AZ-NX-MDL-00799276	AZ-NX-MDL-00799282		Hearsay

Pl. Ex.	Description	Date	Dep. Doc.	End. Doc.	Additional Dates	REVIEWED OBJECTION
0515	File wrapper for United States Patent Application Serial No. 09/387,945 ('103 patent)	09/01/1999	DPCP-Patent-0002375	DPCP-Patent-0002449		
0516	File wrapper for United States Patent Application Serial No. 09/461,148 ('148 patent)	12/15/1999	DPCP-Patent-0002450	DPCP-Patent-0002506		
0517	File wrapper for United States Patent Application Serial No. 09/485,218 ('810 patent)	02/04/2000	DPCP-Patent-0002507	DPCP-Patent-0002643		
0518	File wrapper for United States Patent Application Serial No. 08/690,044 ('872 patent)	10/15/2000	DPCP-Patent-0002644	DPCP-Patent-0003632		
0519	File wrapper for United States Patent Application Serial No. 10/672,936 ('070 patent)	09/25/2003	DPCP-Patent-0003633	DPCP-Patent-0004244		
0520	Letter from Ranbaxy Pharmaceuticals, Inc. to AstraZeneca (Paragraph IV Letter) with enclosure	10/14/2005	RAN-ESM0019845	RAN-ESM0019954		
0521	Letter from Ranbaxy to AstraZeneca counsel	11/14/2005	NEX-RBX 3426760	NEX-RBX 3426760		Hearsay; Incomplete
0522	Letter from IVAX Pharmaceuticals, Inc. to AstraZeneca (Paragraph IV Letter)	01/25/2006	NEX-RBX 2074553	NEX-RBX 2074613		
0523	Letter from IVAX Pharmaceuticals, Inc. to AstraZeneca (Paragraph IV Letter)	02/10/2006	NEX-RBX 2074614	NEX-RBX 2074622		
0524	Letter from Dr. Reddy's Laboratories, Inc. to AstraZeneca (Paragraph IV Letter)	08/17/2006	NEX-RBX 2074623	NEX-RBX 2074650		
0525	Letter from Dr. Reddy's Laboratories, Inc. to AstraZeneca (Paragraph IV Letter)	09/08/2006	NEX-RBX 2074651	NEX-RBX 2074678		
0526	Letter from Matrix Laboratories, Ltd. to AstraZeneca (Paragraph IV Letter)	07/24/2007	[no bates]			Authenticity; Hearsay; Double Hearsay; Relevance
0527	Letter from Dr. Reddy's Laboratories, Inc. to AstraZeneca (Paragraph IV Letter)	12/04/2007	DRLMDL 005963	DRLMDL 006045		
0528	Letter from Ranbaxy, Inc. to AstraZeneca (Paragraph IV Letter)	08/14/2008	AZ-NX-MDL-01238472	AZ-NX-MDL-01238482		Hearsay
0529	Letter from Matrix Laboratories, Ltd. to AstraZeneca (Paragraph IV Letter)	08/22/2008	[no bates]			Authenticity; Hearsay; Double Hearsay; Relevance; Misleading
0530	Letter from IVAX Pharmaceuticals, Inc. to AstraZeneca (Paragraph IV Letter)	08/25/2008	AZ-NX-MDL-00682557	AZ-NX-MDL-00682566		Hearsay
0531	Letter from Sandoz, Inc. to AstraZeneca (Paragraph IV Letter)	12/22/2008	NONPARTY_SANDOZ00021179	NONPARTY_SANDOZ00021249		Authenticity; Hearsay
0532	Letter from Lupin Ltd. to AstraZeneca (Paragraph IV Letter)	09/08/2009	[no bates]			Authenticity; Hearsay
0533	Letter from Dr. Reddy's Laboratories, Inc. to AstraZeneca (Paragraph IV Letter)	12/17/2009	AZ-NX-MDL-00909519	AZ-NX-MDL-00909566		
0534	Letter from Hetero Drug Limited Unit III to AstraZeneca (Paragraph IV Letter)	06/17/2011	[no bates]			Authenticity; Hearsay

Pl. Ex.	Description	Date	Dep. Doc.	Exhibit	Additional Bates	REVISION ACTION	
0535	Letter from Torren Pharmaceuticals Ltd. to AstraZeneca (Paragraph IV Letter)	12/15/2011	[no bates]				Authenticity; Hearsay; Double Hearsay; Relevance; Misleading
0536	Letter from Mylan Laboratories Ltd. to AstraZeneca (Paragraph IV Letter)	01/24/2012	[no bates]				Authenticity; Hearsay
0537	Letter from Watson Laboratories, Inc. - Florida to AstraZeneca (Paragraph IV Letter)	02/04/2013	[no bates]				Authenticity; Hearsay; Double Hearsay; Relevance; Misleading
0538	Letter from Wockhardt Limited to AstraZeneca (Paragraph IV Letter)	06/28/2013	[no bates]				Authenticity; Hearsay; Double Hearsay; Relevance; Misleading
0539	Andersen KK, Tetrahedron Lett. 1962;3:93-5.	undated	[no bates]				Authenticity; Hearsay; Double Hearsay; Relevance; Misleading
0542	European patent application EP 0 005 129 A1	10/31/1979	[no bates]				Hearsay
0544	European patent specification EP 0 005 129 B1	04/29/1981	[no bates]				Hearsay
0545	United States Patent No. 4,337,257	06/29/1982	[no bates]				Hearsay
0548	Pichren P, Dušech E, Deshmukh MN, Kagan HB. J Am Chem Soc. 1984;106(26):8188-93.	01/01/1984	DPCP-Patent-0004400	DPCP-Patent-0004405			Hearsay
0549	Di Fuira F, Modena G Seraglia. Synthesis. 1984 Apr;1984:325-6.	04/01/1984	[no bates]				Hearsay
0550	United States Patent No. 4,472,409	09/18/1984	[no bates]				Hearsay
0551	Gugler R, Jensen JC. Gastroenterology. 1985;89(6):1235-1241.	01/01/1985	[no bates]				Hearsay
0552	Kagan HB, Dušech E, Nemecek C, et al. Pure Appl Chem. 1985;57(12):1911-6. [marked as Plaintiffs' Exhibit 159 in No. 05-cv-05553 (D.N.J.)]	01/01/1985	AZ-NX-MDL-00802586	AZ-NX-MDL-00802591			Hearsay
0554	[Society of Japanese Pharmacopoeia]. Iyakuhin seito shishin [Pharmaceutical manufacturing guidelines]. 1985 ed. Tokyo: [The Pharmaceutical Times Co.]; 1985. Japanese, English.	10/22/1985	[no bates]				Hearsay
0556	Schreiber SL, Schreiber TS, Smith DB. J Am Chem Soc. 1987;109(5):1525-9.	01/01/1987	[no bates]				Hearsay
0557	Sigrist-Nelson K, Krasso A, McKeller RK, Fischl AE. Ro 18-5364, a potent new inhibitor of the gastric (H+ and K+)-ATPase. Eur J Biochem. 1987;166:453-9.	01/01/1987	NEX-RBX 0464502	NEX-RBX 0464508			Hearsay
0558	Zhao SH, Samuel O, Kagan HB. Tetrahedron. 1987;43(21):5135-44.	01/01/1987	DRLMDL 199528	DRLMDL 199537			Hearsay
0559	U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances. Rockville (MD): U.S. Food and Drug Administration; 1987 Feb.	02/01/1987	[no bates]				Hearsay
0560	Smith RL, Caldwell J. Trends Pharmacol Sci. 1988;9(3):75-7.	03/01/1988	[no bates]				Hearsay
0562	Kagan HB, Reblere F, Synlett. 1990;1990(11):603-50.	01/01/1990	DPCP-Patent-0004416-23	DPCP-Patent-0004416-23			Hearsay

Ex-14	Description	Date	Dep Doc	Ex Doc	Additional Bates	REVISOR OBJECTION
0564	Regardh CG, Andersson T, Lagerstrom P-O, et al. Ther Drug Monit. 1990;12(2):163-172.	03/01/1990	[no bates]			Hearsay
0565	Andersson T, Regardh CG, Dahl-Puustinen ML, et al. Ther Drug Monit. 1990;12(4):415-6.	07/01/1990	[no bates]			Hearsay
0567	Kromer W, Postluis S, Riedel R, et al. J Pharmacol Exp Ther. 1990;254(1):129-35.	07/01/1990	[no bates]			Hearsay
0568	Miwa K, Mitani M, Tsukamoto T, et al. Jpn Pharmacol Ther. 1990;18(9):165-87. English translation.	09/01/1990	[no bates]			Hearsay
0570	Erlansson P, Isaksson R, Lorentzen P, Lindberg P. J Chromatogr. 1990;532(2):305-319.	11/16/1990	DPCF-Patent-0001811	DPCF-Patent-0001825		Hearsay
0571	Hamaier G, Graf U, Meissner T. Meth Find Exp Clin Pharmacol. 1991;13(1):63-67.	01/01/1991	[no bates]			Hearsay
0573	Simon WA, Budingen C, Fahr S, et al. Biochem Pharmacol. 1991;42(2):347-51.	07/05/1991	[no bates]			Hearsay
0574	Ariens EJ. Eur J Clin Pharmacol. 1991;41(2):89-93.	08/01/1991	[no bates]			Hearsay
0577	Andersson T, Regardh CG, Lou YC, et al. Pharmacogenetics. 1992;2:25-31.	01/01/1992	[no bates]			Hearsay
0578	Carlson R. Design and optimization in organic synthesis. Amsterdam: Elsevier Science Publishers; 1992. p. 13-15.	01/01/1992	[no bates]			Hearsay
0579	Physicians' Desk Reference: PDR. 46th ed. Montvale (NJ): Medical Economics Co.; 1992. Prilosec Delayed-Release Capsules; p. 1530-2.	01/01/1992	[no bates]			Hearsay; Incomplete
0580	Sohn DR, Kobayahi K, Chiba K, et al. J Pharmacol Exp Ther. 1992;262(3):1195-202.	03/01/1992	[no bates]			Hearsay
0582	Food and Drug Administration. Announcement: FDA's policy statement for the development of new stereoisomeric drugs. Chirality. 1992;4(5):338-340.	05/01/1992	[no bates]			Authenticity; Hearsay
0583	German patent application DE 40 35 455 A1.	05/14/1992	[no bates]			Hearsay
0584	German patent application DE 40 35 455 A1. English translation.	05/14/1992	DPCF-Patent-0001728	DPCF-Patent-0001746		Incomplete
0585	57 Fed. Reg. 23,249	05/27/1992	[no bates]			Authenticity; Hearsay
0586	FDA's Policy Statement for the Development of New Stereoisomeric Drugs	05/27/1992	NEX-RBX 2514168	NEX-RBX 2514173		Hearsay; Misleading; Relevance
0587	Crom WR. Am J Hosp Pharm. 1992;49 Suppl 1:S9-S14.	09/01/1992	[no bates]			Hearsay
0588	Astra memorandum by P. Lindberg. A Single Enantiomer of Omeprazole ** A Possible Future Follow-Up to Omeprazole	01/04/1993	AZ-NX-MDL-00750940	AZ-NX-MDL-00750947		Authenticity; Hearsay; Unfairly Prejudicial

Exhibit	Description	Date	Dep. Doc.	Ex. Doc.	Additional Data	Revised Objection
0589	AstraZeneca memorandum, Omeprazole, with attachments	01/05/1993	NEX-RBX 2524861	NEX-RBX 2524870		Double Hearsay; Hearsay; Incomplete
0590	Gross M, Cartwright A, Campbell B, et al. Drug Info J. 1993;27(2):453-57.	04/01/1993	[no bates]			Hearsay
0591	Seller JP. Drug Info J. 1993;27(2):485-9.	04/01/1993	[no bates]			Hearsay
0598	Astra H&S minutes. Project Team Meeting; Omeprazole Successors (OS), April 27, 1994.	04/28/1994	NEX-RBX 2058938	NEX-RBX 2058939		Hearsay
0599	Astra document; Omeprazole Successors	05/24/1994	AZ-NX-MDL-00749251	AZ-NX-MDL-00749253		Authenticity; Hearsay
0600	Astra H&S Report No. 2142-43, A Review of Biological Data for H 199/18 and H199/18, Thomas Elebring	08/17/1994	NEX-RBX 2833963	NEX-RBX 2833978		
0602	International patent application WO 94/27988 A1	12/08/1994	[no bates]			
0603	Byrn S, Pfeiffer R, Ganey M, et al. Review: Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res. 1995;12(7):945-54. [marked as Defendants' Exhibit 10.11 in No. 05-cv-05553 (D.N.J.)]	01/01/1995	AZ-NX-MDL-00759752	AZ-NX-MDL-00759761		Hearsay
0604	Cairns AM, Chlou RH, Rogers JD, et al. J Chromatogr B. 1995;666(2):323-8.	01/01/1995	DPC-Patent-0001470	DPC-Patent-0001475		Hearsay
0605	United States Patent No. 5,386,032	01/31/1995	[no bates]			Hearsay
0606	Astra H&S project plan. Project No. 826-11, Omeprazole Successor, H 199/18.	02/21/1995	NEX-RBX 2675435	NEX-RBX 2675458		Hearsay
0609	Astra H&S minutes. Extended Omeprazole Successors meeting, October 20, 1995.	10/26/1995	AZ-NX-MDL-00648906	AZ-NX-MDL-00648909		Hearsay
0610	International patent application WO 96/01623 A1	01/25/1996	[no bates]			Hearsay
0613	AstraZeneca document, Patent Situation for H 199/18 - An Update 97-02-05 [marked as Defendants' Exhibit 113 in No. 05-cv-05553 (D.N.J.)]	02/05/1997	DRJMDL 195122	DRJMDL 195123		Authenticity; Hearsay
0614	United States Patent No. 5,693,818	12/02/1997	[no bates]			
0617	Byrn SR, Pfeiffer RP, Stowell JG. Solid-state chemistry of drugs. 2nd ed. West Lafayette (IN): SSC, Inc.; 1999. Chapter 3, The X-Ray Powder Diffraction Method; p. 59-67	01/01/1999	[no bates]			
0619	Paras NA, MacMillan DW. J Am Chem Soc. 2001;123:4370-4371.	01/01/2001	[no bates]			Hearsay
0620	Yoon TP, MacMillan DW. J Am Chem Soc. 2001;123(12):2911-2.	03/02/2001	[no bates]			Hearsay
0621	International patent application WO 02/062786 A1	08/15/2002	[no bates]			Hearsay

PIEN	Description	Date	BegDoc	EndDoc	Additional Bates	REVISED OBJECTION
0626	FDA, Guidance For Industry, ANDAs: Pharmaceutical Solid Polymorphism, Chemistry, Manufacturing and Controls Information. Draft, Rockville (MD); FDA; 2004 Dec.	11/23/2004	[no bates]			
0627	69 Fed. Reg. 75,987	11/20/2004	[no bates]			Hearsay
0628	International patent application WO 2004/111029 A2	11/23/2004	[no bates]			Misleading
0629	Letter from AstraZeneca to the FDA	03/14/2005	[no bates]			Hearsay
0630	Fujima Y, Kunaka M, Inoue T, Matsumoto J. Org Process Res Dev. 2006;10(5):905-13.	01/01/2006	[no bates]			Authenticity: Hearsay
0635	Raju SV, Purandhar K, Reddy PP, et al. Org Process Res Dev. 2006;10(1):35-5.	01/01/2006	[no bates]			Hearsay
0636	Darrow. 2007 Stan. Tech. L. Rev. 2	01/01/2007	[no bates]			Hearsay
0637	United States Patent No. 7,169,793	01/30/2007	[no bates]			Hearsay
0638	Cipla document, Esomeprazole Magnesium Dihydrate Delayed Release Capsules [marked as Plaintiffs' Exhibit 212 in No. 05-cv-05553 (D.N.J.)]	02/01/2007	DRLMDL 197400	DRLMDL 197412		
0639	FDA, Guidance For Industry, ANDAs: Pharmaceutical Solid Polymorphism, Chemistry, Manufacturing and Controls Information. Rockville (MD); FDA; 2007 Jul.	07/01/2007	[no bates]			Hearsay
0640	Atkins P, Jones L. Chemical Principles: The Quest for Insight. 4th ed. New York: W.H. Freeman and Co.; 2008. Chapter 18.2, Isomers; p. 734-7.	01/01/2008	[no bates]			
0641	International patent application WO 2008/017020 A2	02/07/2008	[no bates]			Hearsay
0642	International patent application WO 2008/045777 A2	04/17/2008	[no bates]			Hearsay
0644	AstraZeneca response document. Replies to questions posed at the meeting between the MEB and AstraZeneca on 29 July 2008 regarding generic applications for esomeprazole. Includes Appendix A: Esomeprazole - development and properties.	08/28/2008	AZ-NX-MDL-00669383	AZ-NX-MDL-00669434		Hearsay
0656	Florence AT, Attwood D. Physicochemical principles of pharmacy. 5th ed. London: Pharmaceutical Press; 2011. Figure 1.1. Classification of solids; p. 8.	01/01/2011	[no bates]			Hearsay
0660	United States Pharmacopeial Convention. The United States pharmacopoeia. The national formulary. USP 35th rev., NF 30th ed. Vol 2. Rockville (MD): The Convention; 2011. Esomeprazole magnesium; p. 3097-9.	11/01/2011	AZ-NX-MDL-01270611	AZ-NX-MDL-01270615		Authenticity: Hearsay

Ex-1	Description	Date	Dep. Doc.	Ex-1 Doc.	Additional Dates	REVIEWED OBJECTION
0663	Cacere G. Kong CM, Alleva JL, MacMillan DW. J Am Chem Soc. 2013;135:11521-4.	01/01/2013	[no bates]			Hearsay
0665	Pinot MT, Rankic DA, Martin DB, MacMillan DW. Science. 2013 Mar 29;339(6127):1593-6. Accompanied by: Supplementary Materials in pdf. p. S1-S57.	03/29/2013	[no bates]			
0666	Trout-11: Opinion, Dkt. 142, No. 11-cv-02317 (D.N.J.)	05/01/2013	DRUMDL 219158	DRUMDL 219177		Hearsay
0672	Thin layer chromatography and color markers, or chromatography for kids. Science Project Lab website. http://www.scienceprojectlab.com/tin-layer-chromatography-for-kids.html . Accessed on August 22, 2013.	08/22/2013	[no bates]			
0677	Astra presentation. Omeprazole Successors.	undated	NEX-RBX 0576198	NEX-RBX 0576240		Hearsay
0678	AstraZeneca SR #61399, NEXIUM-History of NEXIUM	undated	NEX-RBX 0600564	NEX-RBX 0600585		Hearsay; Incomplete
0681	HAssie lab notebook pages with translations	undated	[no bates]			Authenticity; Hearsay; Incomplete
0684	Case COMPIA 37.507/F3 - AstraZeneca, Commission Decision CJ(2005) 1757	06/15/2005	[no bates]			Authenticity; Hearsay
0685	Case T-321/05, AstraZeneca AB v. Comm'n, [2010] E.C.R. II-2830	07/01/2010	[no bates]			Authenticity; Hearsay; Relevance; Misleading; Unfairly Prejudicial
0686	Case C-457/10 P, AstraZeneca AB v. Comm'n, Judgment	12/06/2012	[no bates]			Authenticity; Hearsay; Misleading; Unfairly Prejudicial
0688	Development of New Stereoisomeric Drugs. FDA website. http://www.fda.gov/drugs/guidance/ComplianceRegulatoryInformation/Guidances/ucm122883.htm	05/01/1992	[no bates]			Authenticity; Hearsay; Misleading; Relevance; Unfairly Prejudicial
0689	LegalMetric Custom Report. Prevailing Accused Infringers in Patent Cases Where Six or More Patents Were Asserted.	05/01/2013	[no bates]			Authenticity; Hearsay
0690	Anderson T, Cederberg C, Regardh C, G, Skanberg I. Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol. 1990;39:195-97.	03/01/1990	[no bates]			Hearsay
0701	Civil Docket, No. 05-cv-05553 (D.N.J.)	04/11/2013	[no bates]			Hearsay
0702	Complaint, Dkt. 1, No. 05-cv-05553 (D.N.J.)	11/21/2005	Dkt. 1, No. 05-cv-05553 (D.N.J.)			Hearsay; Relevance
0703	Answer, Dkt. 3, No. 05-cv-05553 (D.N.J.)	01/30/2006	Dkt. 3, No. 05-cv-05553 (D.N.J.)			Hearsay; Relevance
0704	Answer to Counterclaim, Dkt. 9, No. 05-cv-05553 (D.N.J.)	02/17/2006	Dkt. 9, No. 05-cv-05553 (D.N.J.)			Relevance
0705	Letter from AstraZeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/17/2006	NEX-RBX 3427268	NEX-RBX 3427274		Hearsay; Relevance
0706	Letter Order, Dkt. 14, No. 05-cv-05553 (D.N.J.)	05/11/2006	Dkt. 14, No. 05-cv-05553 (D.N.J.)			Hearsay; Relevance

Page #	Description	Date	Deposition	Exhibit	Additional Bates	Revised Objection
0709	Order, Dkt. 22, No. 05-cv-05553 (D.N.J.)	09/25/2006	Dkt. 22, No. 05-cv-05553 (D.N.J.)			Relevance
0712	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	11/09/2006	NEX-RBX 3426542	NEX-RBX 3426545		Hearsay, Relevance
0713	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	11/17/2006	NEX-RBX 3426550	NEX-RBX 3426550		Hearsay, Relevance
0714	Minutes and transcript of telephone conference, No. 05-cv-05553 (D.N.J.)	11/20/2006	Dkt. 28, No. 05-cv-05553 (D.N.J.)	NEX-RBX 3426488 - NEX-RBX 3426491		Relevance; Misleading
0717	Preliminary Scheduling Order, Dkt. 29, No. 05-cv-05553 (D.N.J.)	12/01/2006	Dkt. 29, No. 05-cv-05553 (D.N.J.)			Hearsay, Relevance
0718	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	12/18/2006	NEX-RBX 3426449	NEX-RBX 3426451		Hearsay; Misleading; Relevance
0722	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	01/12/2007	NEX-RBX 3426554	NEX-RBX 3426558		Hearsay; Relevance
0725	Letter from AstraZeneca to Magistrate Judge Bongiovanni with attached Declaration of Renea Sekino in Support, No. 05-cv-05553 (D.N.J.)	01/21/2007	NEX-RBX 3426482	NEX-RBX 3426487		Relevance
0726	Letter from Ranbaxy counsel and Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	01/26/2007	NEX-RBX 3427186	NEX-RBX 3427187		Double Hearsay; Hearsay; Relevance
0728	Minutes and transcript of telephone conference, No. 05-cv-05553 (D.N.J.)	03/14/2007	Dkt. 35, No. 05-cv-05553 (D.N.J.)	NEX-RBX 3426583		Relevance; Misleading; Relevance
0730	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/11/2007	NEX-RBX 3426560	NEX-RBX 3426633		Relevance
0731	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/13/2007	NEX-RBX 3426586	NEX-RBX 3427171		Hearsay; Relevance; Unfairly Prejudicial
0732	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/17/2007	NEX-RBX 3427146	NEX-RBX 3426654		Double Hearsay; Hearsay
0733	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/20/2007	NEX-RBX 3426634	NEX-RBX 3426609		Hearsay
0734	Letter from AstraZeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/25/2007	NEX-RBX 3426655	NEX-RBX 3426628		Relevance
0735	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/26/2007	NEX-RBX 3426610	NEX-RBX 3426964		Hearsay; Relevance
0737	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/01/2007	NEX-RBX 3426963	Teva-ESO-029820		Hearsay
0738	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/07/2007	Teva-ESO-029812	NEX-RBX 3427196		Double Hearsay; Hearsay; Unfairly Prejudicial; Relevance
0739	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/08/2007	NEX-RBX 3427193			

File #	Description	Date	Reg Doc	Exhibit	Additional Dates	REVISOR OBJECTION
0740	Letter from AstraZeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/11/2007	Teva-ESO-029821-93	Teva-ESO-029821-93		Hearsay
0741	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/17/2007	NEX-RBX 3427198	NEX-RBX 3427204		Double Hearsay; Hearsay; Relevance
0742	Letter Order, Dkt. 39, No. 05-cv-05553 (D.N.J.)	06/27/2007	Dkt. 39, No. 05-cv-05553 (D.N.J.)			Hearsay; Relevance
0743	AstraZeneca's Motion for a Letter of Request to Take a Deposition in Germany and Obtain Documents Related to the DE '455 Patent Application, and Memorandum in Support of AstraZeneca's Motion for a Letter of Request to Take a Deposition and Collect Documents in Germany, No. 05-cv-05553 (D.N.J.)	07/02/2007	NEX-RBX 3426967	NEX-RBX 3426967	NEX-RBX 3426979 - NEX-RBX 3426982	
0744	Ranbaxy's Responses and Objections to AstraZeneca's First Set of Request for Admissions (Nos. 1-554), No. 05-cv-05553 (D.N.J.)	07/16/2007	NEX-RBX 3424279	NEX-RBX 3424630		Relevance
0746	Letter from Ranbaxy counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	07/19/2007	RAN-ESM0000244	RAN-ESM0000250		Hearsay; Relevance
0747	Letter from AstraZeneca counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	07/22/2007	AZ-NX-MDL-01238466	AZ-NX-MDL-01238471		Hearsay; Relevance
0748	Memorandum of Defendants Ivax Corp., Ivax Pharmaceuticals, Inc., Ivax Pharmaceuticals NV, Inc., Teva Pharmaceuticals Industries Ltd, and Teva Pharmaceuticals USA, Inc. in Opposition to AstraZeneca's Motion for a Letter of Request to Take a Deposition and Collect Documents in Germany, No. 05-cv-05553 (D.N.J.)	07/23/2007	Dkt. 41, No. 05-cv-05553 (D.N.J.)			
0749	Letter Order, Dkt. 42, No. 05-cv-05553 (D.N.J.)	08/07/2007	Dkt. 42, No. 05-cv-05553 (D.N.J.)			Hearsay
0752	Letter Order, Dkt. 44, No. 05-cv-05553 (D.N.J.)	08/14/2007	Dkt. 44, No. 05-cv-05553 (D.N.J.)			Double Hearsay; Hearsay
0753	Letter Order, Dkt. 45, No. 05-cv-05553 (D.N.J.)	08/15/2007	Dkt. 45, No. 05-cv-05553 (D.N.J.)			Hearsay
0754	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	08/15/2007	NEX-RBX 3427018	NEX-RBX 3427019		Hearsay; Relevance
0757	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	08/28/2007	NEX-RBX 3427175	NEX-RBX 3427179		Double Hearsay; Hearsay; Relevance
0760	AstraZeneca's Supplemental Response to Ranbaxy's First Set of Interrogatories to Plaintiffs (No. 1), No. 05-cv-05553 (D.N.J.)	09/14/2007	NEX-RBX 3423912	NEX-RBX 3423986		

Case No.	Description	Date	Referred to	End Date	Additional Notes	REVIEWED OBJECTION
0765	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni with Proposed Amended Pretrial Scheduling Order, No. 05-cv-05553 (D.N.J.)	10/05/2007	NEX-RBX 3427142	NEX-RBX 3427145		
0766	Amended Pretrial Scheduling Order, Dkt. 58, No. 05-cv-05553 (D.N.J.)	10/09/2007	Dkt. 58, No. 05-cv-05553 (D.N.J.)			Hearsay, Relevance
0767	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	10/09/2007	NEX-RBX 3427022	NEX-RBX 3427028		
0768	Letter from Ranbaxy counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	10/10/2007	NEX-RBX 3427173	NEX-RBX 3427184		Double Hearsay, Hearsay, Relevance
0770	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	10/24/2007	NEX-RBX 3427029	NEX-RBX 3427030		Hearsay
0772	Ranbaxy's Responses to AstraZeneca's First Set of Contention Interrogatories (Nos. 1-3), No. 05-cv-05553 (D.N.J.)	11/30/2007	NEX-RBX 3423878	NEX-RBX 3423886		Relevance
0773	AstraZeneca's Response to Ranbaxy's Second Set of Requests for Admissions to Plaintiffs (Nos. 142-158), No. 05-cv-05553 (D.N.J.)	12/17/2007	NEX-RBX 3424771	NEX-RBX 3424779		Hearsay
0774	Order, Dkt. 68, No. 05-cv-05553 (D.N.J.)	01/15/2008	Dkt. 68, No. 05-cv-05553 (D.N.J.)			Double Hearsay, Hearsay, Relevance
0775	Letter Order, Dkt. 72, No. 05-cv-05553 (D.N.J.)	01/29/2008	Dkt. 72, No. 05-cv-05553 (D.N.J.)			Hearsay, Relevance
0776	Memorandum Opinion and Order Issued in Conjunction with the Court's Request for International Judicial Assistance Pursuant to the Hague Convention of 18 March 1970 on the Taking of Evidence in Civil or Commercial Matters to the Appropriate Judicial Authority in Sweden, Dkt. 73, No. 05-cv-05553 (D.N.J.)	01/29/2008	Dkt. 73, No. 05-cv-05553 (D.N.J.)			
0777	Order, Dkt. 76 (sealed), No. 05-cv-0553 (D.N.J.)	02/01/2008	NEX-RBX 3417341	NEX-RBX 3417343		Double Hearsay, Hearsay, Relevance
0779	Transcript of hearing, No. 05-cv-05553 (D.N.J.)	04/14/2008	NEX-RBX 0000435	NEX-RBX 0000440		Hearsay, Relevance
0780	Consent Judgment, Dkt. 80, No. 05-cv-05553 (D.N.J.)	04/14/2008	Dkt. 80, No. 05-cv-05553 (D.N.J.)			Hearsay, Relevance
0781	Rule 1006 Summary of AstraZeneca Litigation with Ranbaxy	01/23/2014	[no bates]			Cumulative; Double Hearsay; Hearsay; Incomplete; Misleading; Not a proper summary under Rule 1006; Unfairly Prejudicial
0782	Civil Docket, No. 06-cv-01057 (D.N.J.)	04/11/2013	[no bates]			
0783	Civil Docket, No. 08-cv-02165 (D.N.J.)	04/11/2013	[no bates]			
0784	Civil Docket, No. 08-cv-04993 (D.N.J.)	04/11/2013	[no bates]			
0785	Complaint, Dkt. 1, No. 06-cv-01057 (D.N.J.)	03/08/2006	Dkt. 1, No. 06-cv-01057 (D.N.J.)			
0786	Answer of IVAX Corporation, Dkt. 13, No. 06-cv-01057 (D.N.J.)	04/27/2006	Dkt. 13, No. 06-cv-01057 (D.N.J.)			

File #	Description	Date	Deposited	Exhibit	Additional Entry	Revised Objection
0787	Answer of VAX Pharmaceuticals, Inc., Dkt. 14, No. 06-cv-01057 (D.N.J.)	04/27/2006	Dkt. 14, No. 06-cv-01057 (D.N.J.)			
0788	Answer of Teva Pharmaceuticals USA, Inc., Dkt. 15, No. 06-cv-01057 (D.N.J.)	04/27/2006	Dkt. 15, No. 06-cv-01057 (D.N.J.)			
0789	Answer of VAX Pharmaceuticals NV, Inc., Dkt. 16, No. 06-cv-01057 (D.N.J.)	04/27/2006	Dkt. 16, No. 06-cv-01057 (D.N.J.)			
0794	Letter Order, Dkt. 32, No. 06-cv-01057 (D.N.J.)	08/07/2006	Dkt. 32, No. 06-cv-01057 (D.N.J.)			
0796	Letter from AstraZeneca counsel to Judge Pizzano, No. 06-cv-01057 (D.N.J.)	08/11/2006	NEX-RBX 3426330	NEX-RBX 3426340		Hearsay
0797	Letter from Teva counsel to Judge Pizzano, No. 06-cv-01057 (D.N.J.)	08/11/2006	Teva-ESO-087328	Teva-ESO-067331		Hearsay
0798	Order, Dkt. 40, No. 06-cv-01057 (D.N.J.)	09/25/2006	Dkt. 40, No. 06-cv-01057 (D.N.J.)			
0809	Defendants' Response to Plaintiffs' First Set of Requests for Admission to Teva/VAX (Nos. 1-303), No. 05-cv-05553 (D.N.J.)	07/16/2007	NEX-RBX 3424154	NEX-RBX 3424278		
0817	AstraZeneca's Supplemental Response to Defendants' (Teva's) First Set of Interrogatories to Plaintiffs (No. 1), No. 05-cv-05553 (D.N.J.)	09/14/2007	NEX-RBX 3424006	NEX-RBX 3424061		Hearsay
0820	Notice of Plaintiffs AstraZeneca's Motion for Leave to File an Amended Complaint, with Memorandum in Support and Declaration of Nicole Corona, No. 05-cv-05553 (D.N.J.)	10/19/2007	Dkt. 59, No. 05-cv-05553 (D.N.J.)		Teva-ESO-031842 - Teva-ESO-031859; Teva-ESO-031537 - Teva-ESO-031839	
0821	Defendants Teva/VAX's Opposition to Plaintiffs AstraZeneca's Motion for Leave to File an Amended Complaint, with Declaration of Michael E. Patunas in Support, Dkt. 63, No. 05-cv-05553 (D.N.J.)	11/05/2007	Teva-ESO-018409	Teva-ESO-018459		Hearsay
0824	Order, Dkt. 79, No. 05-cv-05553 (D.N.J.)	03/31/2008	Dkt. 79, No. 05-cv-05553 (D.N.J.)			Relevance
0825	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/23/2008	NEX-RBX 3427084	NEX-RBX 3427086		Hearsay
0827	Letter from DRL counsel to Magistrate Judge Bongiovanni, Nos. 05-cv-05553 (D.N.J.) and 08-cv-00328 (D.N.J.)	04/25/2008	NEX-RBX 3426306	NEX-RBX 3426308		
0828	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/25/2008	NEX-RBX 3427091	NEX-RBX 3427092		Hearsay
0829	Complaint, Dkt. 4, No. 08-cv-02165 (D.N.J.)	04/30/2008	Dkt. 4, No. 08-cv-02165 (D.N.J.)			
0832	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/02/2008	NEX-RBX 3427100	NEX-RBX 3427110		

Case No.	Description	Date	Reg Doc	End Doc	Additional Dates	REVISED OBJECTION
0833	Letter from DRL counsel to Magistrate Judge Bongiovanni, Nos. 05-cv-05553 (D.N.J.) and 08-cv-00328 (D.N.J.)	05/07/2008	NEX-RBX 3426310	NEX-RBX 3426312		Hearsay
0838	Letter Order, Dkt. 82, No. 05-cv-05553 (D.N.J.)	05/28/2008	Dkt. 82, No. 05-cv-05553 (D.N.J.)			Hearsay
0839	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	06/04/2008	NEX-RBX 3426321	NEX-RBX 3426323		Hearsay
0841	Defendants Teva/VAX's Supplemental Opposition to Plaintiffs AstraZeneca's Motion for Leave to File an Amended Complaint, Dkt. 84, No. 05-cv-05553 (D.N.J.)	06/16/2008	Dkt. 84, No. 05-cv-05553 (D.N.J.)			Hearsay
0843	Defendants Teva/VAX's Opposition to Plaintiffs AstraZeneca's Motion to Strike Teva/VAX's Supplemental Opposition, Dkt. 92, No. 05-cv-05553 (D.N.J.)	07/07/2008	Dkt. 92, No. 05-cv-05553 (D.N.J.)			Hearsay
0844	Notice of Defendants' 12(b)(1) Motion to Dismiss for Lack of Subject Matter Jurisdiction or Alternatively For a Stay, Memorandum in Support, [Proposed] Order Granting Defendants' Motion, and Declaration of Anna Brook, Dkt. 8, No. 08-cv-02165 (D.N.J.)	07/08/2008	Dkt. 8, No. 08-cv-02165 (D.N.J.)			Hearsay
0845	Reply Memorandum on AstraZeneca's Motion to Strike Teva's Improper Sur-Reply or Alternatively for Leave to File a Substantive Submission, Dkt. 94, No. 05-cv-05553 (D.N.J.)	07/14/2008	Dkt. 94, No. 05-cv-05553 (D.N.J.)			Hearsay
0846	Plaintiff IVAX Pharmaceuticals, Inc.'s Opposition to Defendants' Motion under Fed. R. Civ. P. 12(b)(1) to Dismiss for Lack of Subject Matter Jurisdiction, with Declaration of Michael E. Patunas, Dkt. 15, No. 08-cv-02165 (D.N.J.)	08/05/2008	Dkt. 15, No. 08-cv-02165 (D.N.J.)			Hearsay
0847	Reply Memorandum in Support of Defendants' 12(b)(1) Motion to Dismiss for Lack of Subject Matter Jurisdiction or Alternatively for a Stay, Dkt. 17, No. 08-cv-02165 (D.N.J.)	08/11/2008	Dkt. 17, No. 08-cv-02165 (D.N.J.)			Hearsay
0848	Opinion and Order, Dkt. 18 and 19, No. 08-cv-02165 (D.N.J.)	08/28/2008	Dkt. 18 and 19, No. 08-cv-02165 (D.N.J.)			Hearsay
0849	Letter from DRL counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.) and No. 08-cv-00328 (D.N.J.)	09/05/2008	ORLMDL 203390	ORLMDL 203391		
0851	Minutes and transcript of hearing, No. 05-cv-05553 and No. 08-cv-00328 (D.N.J.)	09/09/2008	Dkt. 97, No. 05-cv-05553 (D.N.J.)	ORLMDL 191742 - ORLMDL 191821		Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
						Hearsay

Page	Ex.	Description	Date	Page	Revised	Additional	Revised
							OBJECTION
0853		Letter from Teva counsel to Judge Pisano, Dkt. 20, No. 08-cv-02165 (D.N.J.)	09/12/2008	Dkt. 20, No. 08-cv-02165 (D.N.J.)			Hearsay
0855		Complaint, Dkt. 1, No. 08-cv-04993 (D.N.J.)	10/09/2008	Dkt. 1, No. 08-cv-04993 (D.N.J.)			
0856		Letter from Teva counsel to Judge Pisano, Dkt. 21, No. 08-cv-02165 (D.N.J.)	10/09/2008	Dkt. 21, No. 08-cv-02165 (D.N.J.)			Hearsay
0861		Answer, Dkt. 8, No. 08-cv-04993 (D.N.J.)	11/13/2008	Dkt. 8, No. 08-cv-04993 (D.N.J.)			
0863		Letter from Teva counsel to Judge Pisano, No. 08-cv-02165 (D.N.J.)	11/24/2008	DRLMDL 209022			Hearsay; Relevance
0867		Memorandum Opinion and Order, Dkt. 103 and 104, No. 05-cv-05553 (D.N.J.)	12/16/2008	Dkt. 103 and 104, No. 05-cv-05553 (D.N.J.)			
0868		Transcript of proceedings, No. 08-cv-02165 and No. 08-cv-02496 (D.N.J.)	12/17/2008	DRLMDL 180178			Foundation
0869		Amended Complaint, Dkt. 106, No. 05-cv-05553 (D.N.J.)	12/18/2008	Dkt. 106, No. 05-cv-05553 (D.N.J.)			
0872		Answer of Cipla Ltd., Dkt. 22, No. 08-cv-04993 (D.N.J.)	01/08/2009	Dkt. 22, No. 08-cv-04993 (D.N.J.)			Hearsay
0873		Letter from Teva counsel to Judge Pisano, Dkt. 33, No. 08-cv-02165 (D.N.J.)	01/15/2009	Dkt. 33, No. 08-cv-02165 (D.N.J.)			Hearsay
0874		Transcript of case management conference, No. 08-cv-02165 and No. 08-cv-02496 (D.N.J.)	01/16/2009	Teva-ESO-069462			Authenticity; Hearsay; Unfairly Prejudicial
0875		Answer to Amended Complaint, Dkt. 112, No. 05-cv-05553 (D.N.J.)	01/23/2009	Dkt. 112, No. 05-cv-05553 (D.N.J.)			
0876		Joint letter to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	01/23/2009	DRLMDL 209070			Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
0877		Letter Order, Dkt. 114, No. 05-cv-05553 (D.N.J.)	01/27/2009	Dkt. 114, No. 05-cv-05553 (D.N.J.)			Hearsay
0878		Answer of Cipla Ltd., Dkt. 115, No. 05-cv-05553 (D.N.J.)	01/27/2009	Dkt. 115, No. 05-cv-05553 (D.N.J.)			Hearsay
0879		Order, Dkt. 38, No. 08-cv-02165 (D.N.J.)	02/13/2009	Dkt. 38, No. 08-cv-02165 (D.N.J.)			Hearsay
0881		Letter from Teva counsel to Judge Pisano, Dkt. 40, No. 08-cv-02165 (D.N.J.)	02/19/2009	Dkt. 40, No. 08-cv-02165 (D.N.J.)			Hearsay
0882		Transcript of proceedings, No. 08-cv-02165 and No. 08-cv-02496 (D.N.J.)	02/20/2009	DRLMDL 180258			
0883		Order, Dkt. 43, No. 08-cv-02165 (D.N.J.)	02/24/2009	Dkt. 43, No. 08-cv-02165 (D.N.J.)			
0884		Answer, Dkt. 44, No. 08-cv-02165 (D.N.J.)	02/27/2009	Dkt. 44, No. 08-cv-02165 (D.N.J.)			
0885		Plaintiff IVAX Pharmaceuticals, Inc.'s Invalidity Contentions Pursuant to L. Pat. R. 3.6(b), No. 08-cv-02165 (D.N.J.)	03/02/2009	Teva-ESO-108440			
0886		Answer to Defendants' Counterclaim, Dkt. 119, No. 05-cv-05553 (D.N.J.)	03/04/2009	Dkt. 119, No. 05-cv-05553 (D.N.J.)			
0887		Letter from AstraZeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.) and No. 08-cv-000328 (D.N.J.)	03/20/2009	DRLMDL 203861			Hearsay; Relevance

Case No.	Description	Date	Dep. Doc.	End Date	Additional Dates	REVISOR OBJECTION
0888	Order, Dkt. 120, No. 05-cv-05553 (D.N.J.)	03/24/2009	DRLMDL 181192	DRLMDL 181193		Hearsay
0889	Letter from DRL counsel to the Court, Dkt. 121, No. 05-cv-05553 (D.N.J.)	03/25/2009	[no bates]			
0894	Defendants' Disclosure of Asserted Claims and Infringement Contentions, No. 08-cv-02165	04/18/2009	Teva-ESO-033981	Teva-ESO-034056		Authenticity; Double Hearsay; Collateral Issue; Relevance
0896	Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/21/2009	DRLMDL 204149	DRLMDL 204166		Hearsay
0899	Teva/IVAX's Supplemental Response to AstraZeneca's First Set of Contention Interrogatories to Defendant Teva Corporation, No. 05-cv-05553 (D.N.J.)	04/24/2009	AZ-NX-MDL-00807527	AZ-NX-MDL-00807636		Authenticity; Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
0900	Letter from Teva counsel to Judge Pisano, Dkt. 133, No. 05-cv-05553 (D.N.J.)	04/24/2009	Dkt. 133, No. 05-cv-05553 (D.N.J.)			
0901	Amended Scheduling Order, Dkt. 134, No. 05-cv-05553 (D.N.J.)	04/27/2009	Dkt. 134, No. 05-cv-05553 (D.N.J.)			Hearsay
0903	Letter from DRL counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	04/28/2009	DRLMDL 204240	DRLMDL 204241		
0909	Letter from AstraZeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/01/2009	DRLMDL 204265	DRLMDL 204265		Authenticity; Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
0913	AstraZeneca's Second Supplemental Responses and Objections to Defendants' (Teva's) First Set of Interrogatories to Plaintiffs (Nos. 1-5), No. 05-cv-05553 (D.N.J.)	05/04/2009	AZ-NX-MDL-00807174	AZ-NX-MDL-00807351		
0914	Defendant Cipla's Responses to AstraZeneca's First Set of Interrogatories to Defendant Teva/Cipla (Nos. 1-3), No. 05-cv-05553 (D.N.J.)	05/04/2009	AZ-NX-MDL-00807637	AZ-NX-MDL-00807644		
0925	Transcript of proceedings, No. 08-cv-02165 and No. 08-cv-02496 (D.N.J.)	05/18/2009	DRLMDL 192363	DRLMDL 192389		
0929	Letter from Teva counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	05/22/2009	DRLMDL 185068	DRLMDL 185478		Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
0931	Dr. Reddy's Laboratories, Ltd.'s and Dr. Reddy's Laboratories, Inc.'s Opening Claim Construction Brief, with Declaration of Kenneth E. Crowell in Support, No. 05-cv-05553 (D.N.J.)	05/29/2009	DRLMDL 182012	DRLMDL 182041	DRLMDL 182675 - DRLMDL 182774	
0933	Defendants Teva/IVAX and Cipla's Opening Claim Construction Brief, with Certification of Hany W. Rizkalla in Support, No. 05-cv-05553 (D.N.J.)	05/29/2009	DRLMDL 182042	DRLMDL 182076	DRLMDL 186861 - DRLMDL 187258	Hearsay
0952	DRL's Claim Construction Reply Brief, with Declaration of Kenneth E. Crowell in Support, No. 05-cv-05553 (D.N.J.)	06/26/2009	DRLMDL 199601	DRLMDL 199677		Hearsay

P. Ex.	Description	Date	Bates Doc.	E-File Doc.	Additional Bates	REVISED OBJECTION	
						Revised	Objection
0954	Defendants Teva/VAX and Cipia's Reply Claim Construction Brief, with Certification of Hany K. Rickalla in Support, No. 05-cv-05553 (D.N.J.)	06/26/2009	DRLMDL 200077	DRLMDL 200111	AZ-NX-MDL-00816789 - AZ-NX-MDL-00816894		
0955	Joint Claim Construction and Prehearing Statement, No. 05-cv-05553 (D.N.J.)	07/02/2009	AZ-NX-MDL-00817633	AZ-NX-MDL-00817640	AZ-NX-MDL-00817274 - AZ-NX-MDL-00817632		Hearsay
0956	Minutes and Transcript of proceedings, 05-cv-05553 (D.N.J.)	07/13/2009	Dkt. 201, No. 05-cv-05553 (D.N.J.)		DRLMDL 192408 - DRLMDL 192429		Hearsay
0957	Letter from AstraZeneca counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	08/21/2009	DRLMDL 209544	DRLMDL 209544			Hearsay
0958	Letter from AstraZeneca counsel to Judge Pisano, Dkt. 208, No. 05-cv-05553 (D.N.J.)	09/02/2009	Dkt. 208, No. 05-cv-05553 (D.N.J.)				Hearsay
0959	Letter Order, Dkt. 209, No. 05-cv-05553 (D.N.J.)	09/03/2009	Dkt. 209, No. 05-cv-05553 (D.N.J.)				Hearsay
0960	Letter from Teva counsel to Judge Pisano, Dkt. 210, No. 05-cv-05553 (D.N.J.)	09/21/2009	Dkt. 210, No. 05-cv-05553 (D.N.J.)				Hearsay
0961	Letter from DRL counsel to Magistrate Judge Bongiovanni, No. 08-cv-02165 (D.N.J.) and No. 08-cv-02496 (D.N.J.)	10/19/2009	DRLMDL 216361	DRLMDL 216362			Hearsay
0963	Letter from DRL counsel to Magistrate Judge Bongiovanni, No. 08-cv-02165 (D.N.J.) and No. 08-cv-02496 (D.N.J.)	10/21/2009	DRLMDL 204641	DRLMDL 204642			Double Hearsay; Hearsay
0965	Consent Judgment, Dkt. 213, No. 05-cv-05553 (D.N.J.)	01/07/2010	Dkt. 213, No. 05-cv-05553 (D.N.J.)				
0966	Rule 1005 Summary of AstraZeneca Litigation with Teva	01/23/2014	[no bates]				Cumulative; Double Hearsay; Hearsay; Not a proper summary under Rule 1005
0967	Civil Docket, No. 08-cv-00328 (D.N.J.)	04/11/2013	[no bates]				
0968	Civil Docket, No. 08-cv-02496 (D.N.J.)	04/11/2013	[no bates]				
0969	Complaint, Dkt. 1, No. 08-cv-00328 (D.N.J.)	01/17/2008	Dkt. 1, No. 08-cv-00328 (D.N.J.)				
0970	Answer and Counterclaims, Dkt. 8, No. 08-cv-00328 (D.N.J.)	02/12/2008	Dkt. 8, No. 08-cv-00328 (D.N.J.)				
0971	Letter from DRL counsel to the Court, No. 08-cv-00328 (D.N.J.)	02/12/2008	NEX-RBX 3427055	NEX-RBX 3427059			Hearsay; Double Hearsay; Collateral Issue; Relevance
0974	Answer to Counterclaim, Dkt. 13, No. 08-cv-00328 (D.N.J.)	03/05/2008	Dkt. 13, No. 08-cv-00328 (D.N.J.)				Hearsay
0975	Joint letter to Magistrate Judge Bongiovanni, No. 08-cv-00328 (D.N.J.)	03/18/2008	NEX-RBX 3427066	NEX-RBX 3427083			Hearsay
0976	Preliminary Scheduling Order, Dkt. 14, No. 08-cv-00328 (D.N.J.)	04/03/2008	Dkt. 14, No. 08-cv-00328 (D.N.J.)				Hearsay
0977	Complaint, Dkt. 1, No. 08-cv-02496 (D.N.J.)	05/19/2008	Dkt. 1, No. 08-cv-02496 (D.N.J.)				Hearsay
0978	Notice of Defendants' 12(b)(1) Motion to Dismiss for Lack of Subject Matter Jurisdiction or Alternatively for a Stay, Memorandum in Support and Declaration of Anna Brook, Dkt. 6, No. 08-cv-02496 (D.N.J.)	07/08/2008	Dkt. 6, No. 08-cv-02496 (D.N.J.)				Hearsay

PHEN	Description	Date	Case No.	EndDoc	Additional Bates	REVISED OBJECTION
0979	DRL's Objections and Responses to AstraZeneca's First Set of Contention Interrogatories to Defendants (Nos. 1-3), No. 08-cv-00328 (D.N.J.)	07/21/2008	AZ-NX-MDL-00807401	AZ-NX-MDL-00807442		
0981	DRL's Memorandum of Law in Opposition to Defendants' 12(b)(1) Motion to Dismiss for Lack of Subject Matter Jurisdiction or Alternatively for a Stay, with Affidavit of Alan H. Pollack, Dkt. 11 and 12, No. 08-cv-02496 (D.N.J.)	08/04/2008	Dkt. 11 and 12, No. 08-cv-02496 (D.N.J.)			
0982	Reply Memorandum in Support of Defendants' 12(b)(1) Motion to Dismiss for Lack of Subject Matter Jurisdiction or Alternatively for a Stay, Dkt. 13, No. 08-cv-02496 (D.N.J.)	08/11/2008	Dkt. 13, No. 08-cv-02496 (D.N.J.)			Hearsay; Unfairly Prejudicial
0983	Opinion and Order, Dkt. 14 and 15, No. 08-cv-02496 (D.N.J.)	08/28/2008	Dkt. 14 and 15, No. 08-cv-02496 (D.N.J.)			Hearsay
0985	Letter from DRL counsel to Judge Pisano attaching DRL's Notice of Motion for Reconsideration of the Court's August 28, 2008 Decision and Order; Proposed Order Granting DRL's Motion for Reconsideration of the Court's August 28, 2008 Decision and Order and Reopening and Reinstating This Action; and DRL's Memorandum of Law in Support of Its Motion for Reconsideration of the Court's August 28, 2008 Decision and Order, No. 08-cv-02496 (D.N.J.)	09/12/2008	DRLMDL 212740	DRLMDL 212760		Hearsay
0989	Defendants AstraZeneca's Opposition to DRL's Motion for Reconsideration of the Court's August 28, 2008 Decision and Order, Dkt. 23, No. 08-cv-02496 (D.N.J.)	10/06/2008	Dkt. 23, No. 08-cv-02496 (D.N.J.)			Foundation
0990	DRL's Reply to Defendant AstraZeneca's Opposition to DRL's Motion for Reconsideration of the Court's August 28, 2008 Decision and Order, Dkt. 24, No. 08-cv-02496 (D.N.J.)	10/14/2008	Dkt. 24, No. 08-cv-02496 (D.N.J.)			Hearsay
0993	Declaratory Judgment Plaintiffs' Non-Infringement Contentions Respecting the Patents in Suit, No. 08-cv-02496 (D.N.J.)	01/26/2009	DRLMDL 218255	DRLMDL 218291		Hearsay
0994	Letter from DRL counsel to Judge Pisano, Dkt. 37, No. 08-cv-02496 (D.N.J.)	02/19/2009	Dkt. 37, No. 08-cv-02496 (D.N.J.)			
0995	Order, Dkt. 41, No. 08-cv-02496 (D.N.J.)	02/24/2009	Dkt. 41, No. 08-cv-02496 (D.N.J.)			Hearsay; Relevance; Unfairly Prejudicial
0996	Answer, Dkt. 42, No. 08-cv-02496 (D.N.J.)	02/27/2009	Dkt. 42, No. 08-cv-02496 (D.N.J.)			

Case No.	Description	Date	Deposition	Exhibit	Additional Notes	Revised/Objection
0997	Declaratory Judgment Plaintiffs' Non-Infringement Contentions Respecting the Patents in Suit, No. 08-cv-02496 (D.N.J.)	03/02/2009	DRLMDL 218292	DRLMDL 218328		
0998	Declaratory Judgment Plaintiffs' Invalidity Contentions Respecting the Patents in Suit, No. 08-cv-02496 (D.N.J.)	03/02/2009	DRLMDL 218329	DRLMDL 218372		
0999	Letter from DRL counsel to Judge Pisano, Dkt. 28, No. 08-cv-00328 (D.N.J.)	03/20/2009	Dkt. 28, No. 08-cv-00328 (D.N.J.)		Hearsay	
1001	AstraZeneca's Responses and Objections to DRL's Second Set of Interrogatories (Nos. 2-5), No. 05-cv-05553 (D.N.J.)	04/13/2009	DRLMDL 183413	DRLMDL 183538		
1003	DRL's Responses to AstraZeneca's First Set of Requests for Admissions (1-364), No. 05-cv-05553 (D.N.J.)	05/04/2009	DRLMDL 184419	DRLMDL 184603		
1005	DRL's Responses to AstraZeneca's Second Set of Interrogatories (4-6), No. 05-cv-05553 (D.N.J.)	05/06/2009	DRLMDL 209237	DRLMDL 209252		
1013	Letter from DRL counsel to Magistrate Judge Bongiovanni, No. 05-cv-05553 (D.N.J.)	09/09/2009	DRLMDL 204652	DRLMDL 204656		
1017	Minutes and transcript of proceedings, No. 05-cv-05553 (D.N.J.)	01/15/2010	Dkt. 214, No. 05-cv-05553 (D.N.J.)		DRLMDL 192142 - DRLMDL 192164	Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
1019	Letter from DRL counsel to AstraZeneca counsel, No. 05-cv-05553 (D.N.J.)	01/20/2010	DRLMDL 209700	DRLMDL 209704		Incomplete
1021	Letter from DRL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	01/21/2010	DRLMDL 209706	DRLMDL 209746		
1023	Minutes and transcript of proceedings, No. 05-cv-05553 (D.N.J.)	01/22/2010	Dkt. 215, No. 05-cv-05553 (D.N.J.)		DRLMDL 192166 - DRLMDL 192192	Hearsay
1025	Letter from DRL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	02/03/2010	DRLMDL 209792	DRLMDL 209810		
1027	E-mail from DRL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	02/04/2010	DRLMDL 209833	DRLMDL 209836		Double Hearsay; Hearsay; Unfairly Prejudicial
1028	Judgment Regarding AstraZeneca's Third Claim for Relief and Dismissing DRL Second Counterclaim, Dkt. 216, No. 05-cv-05553 (D.N.J.)	02/05/2010	Dkt. 216, No. 05-cv-05553 (D.N.J.)			Hearsay
1030	Notice of AstraZeneca's Motion for Partial Summary Judgment on DRL's Infringement of U.S. Patent No. 6,875,872, with Declaration of Anna Brook, Memorandum in Support, and Proposed Order, No. 05-cv-05553 (D.N.J.)	03/03/2010	Dkt. 219, No. 05-cv-05553 (D.N.J.)		DRLMDL 211127 - DRLMDL 211127; AZ-NX-MDL-00809091 - AZ-NX-MDL-00809105; DRLMDL 211169 - DRLMDL 211184; DRLMDL 211222 - DRLMDL 211224	

Pl. Ex.	Description	Date	BagDo	Exhib.	Additional Dates	Revised Objection
1032	Notice of Dr. Reddy's Laboratories' Motion for Summary Judgment of Non-Infringement of U.S. Patent Nos. 6,191,148 and 6,428,810 Pursuant to Counts V and VI of its Declaratory Judgment Action, with Memorandum of Law in Support, Statement of Undisputed Facts, Declaration of Dmitry Shelhoff, and [Proposed] Judgments, Dkt. 50, No. 08-cv-02496 (D.N.J.)	03/09/2010	DRLMDL 217507	DRLMDL 217509	DRLMDL 217521 - DRLMDL 217528; DRLMDL 217660 - DRLMDL 217663; DRLMDL 217510 - DRLMDL 217512; DRLMDL 217529 - DRLMDL 217532; DRLMDL 217558 - DRLMDL 217649; DRLMDL 217554 - DRLMDL 217557; DRLMDL 217650 - DRLMDL 217655	
1034	Notice of AstraZeneca's Motion to Stay the Case and for an Extension of AstraZeneca's Time to Oppose DRL's Summary Judgment Motion, with Memorandum in Support, Declaration of Dana Weir and [Proposed Order], Dkt. 58, No. 08-cv-02496 (D.N.J.)	03/19/2010	Dkt. 58, No. 08-cv-02496 (D.N.J.)	DRLMDL 211354 - DRLMDL 211396		Double Hearsay; Hearsay
1036	Letter from DRL counsel to Judge Pisano, No. 05-cv-02496 (D.N.J.)	03/23/2010	DRLMDL 209878	DRLMDL 209879		Hearsay
1037	Minutes and transcript of Markman hearing, No. 05-cv-05553 (D.N.J.)	03/24/2010	Dkt. 225, No. 05-cv-05553 (D.N.J.)		DRLMDL 192216 - DRLMDL 192337	Hearsay
1040	DRL's Memorandum of Law in Opposition to AstraZeneca's Motion to Stay the Case and for an Extension of Time to Oppose DRL's Summary Judgment Motion, Dkt. 64, No. 08-cv-02496 (D.N.J.)	04/05/2010	Dkt. 64, No. 08-cv-02496 (D.N.J.)			
1041	Memorandum in Opposition to DRL's Motion for Summary Judgment of Non-Infringement of U.S. Patent Nos. 6,191,148 and 6,428,810 Pursuant to Counts V and VI of its Declaratory Judgment Action, with Counter-Statement of Facts, Dkt. 65, No. 08-cv-02496 (D.N.J.)	04/05/2010	Dkt. 65, No. 08-cv-02496 (D.N.J.)			Hearsay; Relevance; Unfairly Prejudicial
1042	Letter from DRL counsel to Judge Pisano, Dkt. 230, No. 05-cv-05553 (D.N.J.)	04/09/2010	Dkt. 230, No. 05-cv-05553 (D.N.J.)			Hearsay
1044	Reply Memorandum in Support of AstraZeneca's Motion to Stay the Case, with Declaration of Emily Jayne Kunz, Dkt. 68, No. 08-cv-02496 (D.N.J.)	04/12/2010	Dkt. 68, No. 08-cv-02496 (D.N.J.)			Hearsay
1047	Letter from DRL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	04/21/2010	DRLMDL 204921	DRLMDL 204922		Hearsay
1049	Letter from DRL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	04/26/2010	DRLMDL 205147	DRLMDL 205153		Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
1050	Letter from AstraZeneca counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	04/29/2010	DRLMDL 205165	DRLMDL 205200		Hearsay; Relevance
1051	Letter from DRL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	04/30/2010	DRLMDL 205202	DRLMDL 205204		Double Hearsay; Hearsay; Misleading; Relevance; Unfairly Prejudicial
1052	Order (sealed), No. 05-cv-05553 (D.N.J.)	05/06/2010	DRLMDL 181429	DRLMDL 181431		

Case No.	Description	Date	RegDoc	EndDoc	Additional Bates	REVIEWED OBJECTION
1053	Transcript of proceedings, No. 05-cv-05553 (D.N.J.)	05/06/2010	DRLMDL 192346	DRLMDL 192362		
1055	Opinion and Order, Dkt. 246 and 247, No. 05-cv-05553 (D.N.J.)	05/18/2010	Dkt. 246 and 247, No. 05-cv-05553 (D.N.J.)			
1057	DRL's Supplemental Responses to AstraZeneca's Requests for Admissions Nos. 325-384, No. 05-cv-05553 (D.N.J.)	05/21/2010	DRLMDL 209995	DRLMDL 210031		
1059	Letter from DRL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	05/21/2010	DRLMDL 210042	DRLMDL 210061		Double Hearsay; Hearsay; Unfairly Prejudicial
1061	Transcript of proceedings, No. 05-cv-05553 (D.N.J.)	06/03/2010	DRLMDL 192390	DRLMDL 192407		
1064	Order, Dkt. 265, No. 05-cv-05553 (D.N.J.)	07/12/2010	Dkt. 265, No. 05-cv-05553 (D.N.J.)			
1071	Transcript of Proceedings, No. 05-cv-05553 (D.N.J.)	10/06/2010	DRLMDL 192026	DRLMDL 192046		
1073	Letter from DRL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	10/19/2010	DRLMDL 210144	DRLMDL 210190		Double Hearsay; Hearsay; Misleading; Unfairly Prejudicial
1081	Letter from DRL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	11/12/2010	DRLMDL 208498	DRLMDL 208628		Foundation
1084	Letter from DRL counsel to Judge Pisano, No. 05-cv-05553 (D.N.J.)	11/24/2010	DRLMDL 208629	DRLMDL 208647		Double Hearsay; Hearsay; Unfairly Prejudicial
1086	Minutes and transcript of proceedings, No. 05-cv-05553 (D.N.J.)	12/21/2010	Dkt. 293, No. 05-cv-05553 (D.N.J.)		DRLMDL 192076 - DRLMDL 192104	
1093	Letter from AstraZeneca counsel to Judge Pisano, Dkt. 295, No. 05-cv-05553 (D.N.J.)	01/25/2011	Dkt. 295, No. 05-cv-05553 (D.N.J.)			Hearsay
1094	Consent Judgment, Dkt. 296, No. 05-cv-05553 (D.N.J.)	01/28/2011	Dkt. 296, No. 05-cv-05553 (D.N.J.)			
1095	Rule 1006 Summary of AstraZeneca Litigation with DRL	01/23/2014	[no bates]			Cumulative; Double Hearsay; Hearsay; Not a proper summary under Rule 1006
1096	Complaint, Dkt. 1, No. 09-cv-00199 (D.N.J.)	01/01/2009	Dkt. 1, No. 09-cv-00199 (D.N.J.)			Hearsay
1097	Answer and Counterclaims, Dkt. 11, No. 09-cv-00199 (D.N.J.)	03/06/2009	Dkt. 11, No. 09-cv-00199 (D.N.J.)			Hearsay
1098	Answer and Amended Counterclaims, Dkt. 16, No. 09-cv-00199 (D.N.J.)	04/01/2009	Dkt. 16, No. 09-cv-00199 (D.N.J.)			Hearsay
1099	Consent Order of Dismissal, Dkt. 65, No. 09-cv-00199 (D.N.J.)	06/13/2011	Dkt. 65, No. 09-cv-00199 (D.N.J.)			
1100	Civil Docket, No. 09-cv-00199 (D.N.J.)	12/24/2013	[no bates]			Hearsay; Relevance
1101	Complaint, Dkt. 1, No. 09-cv-05404 (D.N.J.)	10/21/2009	Dkt. 1, No. 09-cv-05404 (D.N.J.)			Hearsay
1102	Answer, Defenses and Counterclaims, Dkt. 12, No. 09-cv-05404 (D.N.J.)	12/11/2009	Dkt. 12, No. 09-cv-05404 (D.N.J.)			Hearsay
1103	Consent Judgment, Dkt. 74, No. 09-cv-05404 (D.N.J.)	01/26/2012	Dkt. 74, No. 09-cv-05404 (D.N.J.)			Hearsay
1104	Civil Docket, No. 09-cv-05404 (D.N.J.)	12/24/2013	[no bates]			Hearsay; Relevance
1105	Complaint, Dkt. 1, No. 11-cv-04468 (D.N.J.)	08/02/2011	Dkt. 1, No. 11-cv-04468 (D.N.J.)			Hearsay
1106	Consent Judgment, Dkt. 23, No. 11-cv-04468 (D.N.J.)	04/17/2012	Dkt. 23, No. 11-cv-04468 (D.N.J.)			
1107	Civil Docket, No. 11-cv-04468 (D.N.J.)	12/24/2013	[no bates]			Hearsay; Relevance

Index	Description	Date	Exhibit	EndDoc	Additional Bates	RELEVANT OBJECTION
1108	Complaint, Dkt. 1, No. 12-cv-00506 (D.N.J.)	01/26/2012	Dkt. 1, No. 12-cv-00506 (D.N.J.)			Hearsay
1109	Consent Judgment, Dkt. 12, No. 12-cv-00506 (D.N.J.)	05/18/2012	Dkt. 12, No. 12-cv-00506 (D.N.J.)			
1110	Civil Docket, No. 12-cv-00506 (D.N.J.)	12/24/2013	[no bates]			Hearsay; Relevance
1111	First Amended Complaint, Dkt. 52, No. 12-cv-01378 (D.N.J.)	11/14/2012	Dkt. 52, No. 12-cv-01378 (D.N.J.)			Hearsay
1112	Answer, Separate Defenses and Counterclaims to First Amended Complaint, Dkt. 57, No. 12-cv-01378 (D.N.J.)	12/04/2012	Dkt. 57, No. 12-cv-01378 (D.N.J.)			
1113	AstraZeneca's Brief in Support of its Motion to Amend the Complaint to Assert Infringement of U.S. Patent No. 5,948,789, Dkt. 105-6, No. 12-cv-01378 (D.N.J.)	06/21/2013	Dkt. 105-6, No. 12-cv-01378 (D.N.J.)			Hearsay
1114	Civil Docket, No. 12-cv-01378 (D.N.J.)	09/20/2014	[no bates]			Hearsay; Relevance
1115	Complaint, Dkt. 1, No. 13-cv-01669 (D.N.J.)	03/19/2013	Dkt. 1, No. 13-cv-01669 (D.N.J.)			Hearsay
1116	Answer, Separate Defenses and Counterclaims, Dkt. 9, No. 13-cv-01669 (D.N.J.)	06/03/2013	Dkt. 9, No. 13-cv-01669 (D.N.J.)			Hearsay
1117	Civil Docket, No. 13-cv-01669 (D.N.J.)	09/20/2014	[no bates]			Hearsay
1118	Complaint, Dkt. 1, No. 13-cv-04854 (D.N.J.)	08/12/2013	Dkt. 1, No. 13-cv-04854 (D.N.J.)			Hearsay; Relevance
1119	Civil Docket, No. 13-cv-04854 (D.N.J.)	09/20/2014	[no bates]			Hearsay
1120	Complaint, Dkt. 1, No. 13-cv-07298 (D.N.J.)	12/03/2013	Dkt. 1, No. 13-cv-07298 (D.N.J.)			Hearsay; Relevance
1121	Civil Docket Sheet, No. 13-cv-07298 (D.N.J.)	09/20/2014	[no bates]			Hearsay; Relevance
1122	Complaint, Dkt. 1, No. 13-cv-07299 (D.N.J.)	12/03/2013	Dkt. 1, No. 13-cv-07299 (D.N.J.)			Hearsay; Relevance
1123	Civil Docket Sheet, No. 13-cv-07299 (D.N.J.)	09/20/2014	[no bates]			Hearsay; Relevance
1124	Letter from AstraZeneca counsel to Ranbaxy	10/25/2005	RAN-ESM0088194	RAN-ESM0088197		Authenticity; Hearsay; Relevance
1125	Letter from Ranbaxy to AstraZeneca counsel	10/27/2005	NEX-RBX 3426749	NEX-RBX 3426750		Hearsay; Relevance
1126	Letter from AstraZeneca counsel to Ranbaxy	10/31/2005	NEX-RBX 3426808	NEX-RBX 3426809		Hearsay; Relevance
1127	Letter from Ranbaxy to AstraZeneca counsel	11/02/2005	NEX-RBX 3426752	NEX-RBX 3426753		Double Hearsay; Hearsay; Relevance
1128	Letter from Ranbaxy counsel to AstraZeneca counsel	11/04/2005	RAN-ESM0088295	RAN-ESM0088295		Authenticity; Hearsay; Relevance
1129	Letter from Ranbaxy counsel to AstraZeneca counsel	11/07/2005	RAN-ESM0088293	RAN-ESM0088294		Authenticity; Hearsay; Relevance
1130	Letter from Ranbaxy counsel to AstraZeneca counsel	11/11/2005	RAN-ESM0088291	RAN-ESM0088292		Authenticity; Hearsay; Unfairly Prejudicial; Relevance
1131	Letter from AstraZeneca counsel to IVAX	02/06/2006	Teva-ESO-032242	Teva-ESO-032244		Authenticity; Incomplete
1132	Letter from IVAX counsel to AstraZeneca counsel	02/13/2006	Teva-ESO-032240	Teva-ESO-032240		Authenticity; Incomplete

Pl. Ex.	Description	Date	Reg. Doc.	End Doc.	Additional Bates	REVISOR OBJECTION
1133	Letter from DRL counsel to AstraZeneca counsel, No. 05-cv-05553 (D.N.J.)	05/26/2010	AZ-NX-MDL-00000534	AZ-NX-MDL-00000535		Hearsay
1134	Rule 1006 Summary of Other AstraZeneca Litigation	02/08/2014	[no bates]			Cumulative; Double Hearsay; Hearsay; Unfairly Prejudicial; Not a proper summary under Rule 1006
1138	Answer and Amended Counterclaims of Defendant Sandoz Inc., Dkt. 19, No. 09-cv-00199 (D.N.J.)	05/06/2009	[no bates]			Hearsay
1139	Sandoz Complaint against Merck, Dkt. 23, No. 09-cv-00199 (D.N.J.)	05/12/2009	[no bates]			Hearsay
1140	Sandoz's Memorandum in Opposition to Plaintiffs' Counterclaim-Defendants' Motion to Stay the Case and Bifurcate Amended Counterclaims XI-XVI, Dkt. 28, No. 09-cv-00199 (D.N.J.)	06/01/2009	[no bates]			Hearsay
1141	Defendants Mylan Inc. and Mylan Laboratories Limited's Amended Answer, Separate Defenses and Counterclaims to First Amended Complaint, Dkt. 78, No. 12-cv-01378 (D.N.J.)	02/25/2013	[no bates]			Hearsay
1142	Defendants Wockhardt Limited and Wockhardt USA LLC's Answer, Affirmative Defenses and Counterclaims, Dkt. 8, No. 13-cv-04854 (D.N.J.)	11/20/2013	[no bates]			Hearsay
1143	Letter from AstraZeneca counsel to DRL counsel, No. 05-cv-05553 (D.N.J.), with fax cover sheet	03/03/2010	DRLMDL 211124	DRLMDL 211125		Hearsay
1151	Astra Hässle Clinical Study Report No. SH-QBE-0001	01/16/1997	NEX-RBX 0002670	NEX-RBX 0002821		Authenticity; Hearsay
1152	Astra Merck Protocol No. 172, Draft	04/07/1997	NEX-RBX 2893368	NEX-RBX 2893415		Relevance
1153	Astra Hässle Clinical Study Report No. SH-QBE-0002	04/11/1997	NEX-RBX 2429078	NEX-RBX 2429111		Hearsay
1154	Astra Hässle Clinical Study Report No. SH-QBE-0008	04/14/1997	AZ-NX-MDL-00669509	AZ-NX-MDL-00669538		Incomplete
1155	Astra Pharmaceuticals, L.P. Data Analysis Plan for H199/18 Protocol 172, Draft Tables	06/11/1998	NEX-RBX 2351679	NEX-RBX 2351727		Authenticity; Hearsay; Incomplete; Relevance
1156	Astra Pharmaceuticals, L.P. Data Analysis Plan for H199/18 Protocol 172, Draft	06/16/1998	NEX-RBX 2351676	NEX-RBX 2351678		Authenticity; Hearsay; Incomplete
1157	Astra Pharmaceuticals, L.P. Data Analysis Plan for H199/18 Protocol 172, Draft	07/07/1998	NEX-RBX 2351728	NEX-RBX 2351735		Authenticity; Hearsay; Incomplete
1158	Astra Pharmaceuticals, L.P. Clinical Study Report 172, Draft	12/14/1998	NEX-RBX 2887521	NEX-RBX 2887628		Hearsay
1159	Notes for Nexium Presentation, Lisa Schoenberg, presenter	01/05/1999	AZ-NX-MDL-01232432	AZ-NX-MDL-01232436		Hearsay; Relevance
1160	Astra Pharmaceuticals, L.P. Clinical Study Report 172, Draft	01/27/1999	NEX-RBX 2089937	NEX-RBX 2090044		Incomplete
1161	Astra Hässle minutes, January 25, 1999 Esomeprazole (H199/18) European Marketing Strategy Meeting	02/17/1999	AZ-NX-MDL-00651706	AZ-NX-MDL-00651715		Incomplete
1162	Astra Hässle Clinical Study Report No. SH-QBE-0021	04/27/1999	AZ-NX-MDL-00680129	AZ-NX-MDL-00680241		Hearsay

Index	Description	Date	Depos	Exhib	Additional Dates	REVISED OBJECTION
1163	Astra HÅssle Clinical Study Report No. SH-Q8E-0009	05/12/1999	AZ-NX-MDL-00679705	AZ-NX-MDL-00679875		
1164	Astra HÅssle Clinical Study Report No. SH-Q8E-0011	05/12/1999	AZ-NX-MDL-00679982	AZ-NX-MDL-00680118		
1165	Astra Pharmaceuticals, L.P. Clinical Study Report 172, without appendices	05/20/1999	NEX-RBX 0138618	NEX-RBX 0139032		
1166	Astra Pharmaceuticals, L.P. Clinical Study Report 172, List of Appendices	05/20/1999	NEX-RBX 0139049	NEX-RBX 0139057		Incomplete, Relevance; Unfairly Prejudicial
1167	Astra Pharmaceuticals, L.P. Clinical Study Report 172, Appendix 16.1.1, Astra Merck Protocol No. 172, Amendment No. 1 dated August 29, 1997	05/20/1999	NEX-RBX 0139058	NEX-RBX 0139127		Incomplete, Relevance
1168	Astra Pharmaceuticals, L.P. Clinical Study Report 172, Appendix 16.1.9, Data Analysis Plan for H199-18 Protocol 172	05/20/1999	NEX-RBX 0139977	NEX-RBX 0139986		Incomplete
1169	Astra HÅssle Clinical Study Report No. SH-Q8E-0060	12/15/1999	NEX-RBX 0064888	NEX-RBX 0065177		Relevance
1170	Astra HÅssle Clinical Study Report No. SH-Q8E-0066	02/10/2000	NEX-RBX 0116132	NEX-RBX 0116469	NEX-RBX 0065760 - NEX-RBX 0065941	Relevance
1171	Video clip (01:clip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/08/2001	AZ-NX-MDL-01240264.wmv (native file)			Hearsay; Relevance; Unfairly Prejudicial
1172	Video clip (03:clip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/08/2001	AZ-NX-MDL-01240266.wmv (native file)			Hearsay; Relevance; Unfairly Prejudicial
1173	Video (VTS_01_1.wmv) from National Nexium Sales Meeting, January 9, 2001	01/09/2001	AZ-NX-MDL-01240379.wmv (native file)			Authenticity; Hearsay; Relevance; Unfairly Prejudicial
1174	Screen shot from video (VTS_01_1.wmv) from National Nexium Sales Meeting, January 9, 2001, at 6:29"	01/09/2001	[no bates]			Authenticity; Hearsay; Incomplete
1175	Video clip (04:clip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/09/2001	AZ-NX-MDL-01240267.wmv (native file)			Hearsay; Relevance; Unfairly Prejudicial
1176	Video clip (05:clip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/09/2001	AZ-NX-MDL-01240268.wmv (native file)			Hearsay; Relevance; Unfairly Prejudicial
1177	Video clip (06:clip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/09/2001	AZ-NX-MDL-01240269.wmv (native file)			Hearsay; Relevance; Unfairly Prejudicial
1178	Video clip (07:clip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/09/2001	AZ-NX-MDL-01240270.wmv (native file)			Hearsay; Relevance; Unfairly Prejudicial
1179	Video clip (09:clip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/10/2001	AZ-NX-MDL-01240272.wmv (native file)			Hearsay; Relevance; Unfairly Prejudicial
1180	Video clip (11:clip.wmv) from National Nexium Sales Meeting, January 8-10, 2001	01/10/2001	AZ-NX-MDL-01240274.wmv (native file)			Hearsay; Relevance; Unfairly Prejudicial
1181	Market Measures Interactive Fastape Plus Study #42186, PPIs: Nexium Wave 1, prepared for AstraZeneca	05/15/2001	AZ-NX-MDL-01235572	AZ-NX-MDL-01235982		Double Hearsay; Hearsay; Relevance

Exhibit	Description	Date	Reg. Doc.	Exhibit Doc.	Additional Dates	REVISED OBJECTION
1182	Market Measures Interactive Fastape Plus Study #42187, Proton Pump Inhibitors: Nexium Wave II, prepared for AstraZeneca	08/03/2001	AZ-NX-MDL-01235983	AZ-NX-MDL-01236604		Double Hearsay; Hearsay; Relevance
1183	TargetRx, Inc. presentation, Launch Tracking for Nexium - Wave 11, prepared for AstraZeneca	11/01/2001	AZ-NX-MDL-01237087	AZ-NX-MDL-01237160		Double Hearsay; Hearsay; Relevance
1184	TargetRx, Inc. presentation, Launch Tracking for Nexium - Wave 12, prepared for AstraZeneca	11/30/2001	AZ-NX-MDL-01237161	AZ-NX-MDL-01237228		Double Hearsay; Hearsay; Relevance
1185	Market Measures Interactive Fastape Plus Study #42413, Nexium Refresh, prepared for AstraZeneca	12/14/2001	AZ-NX-MDL-01236605	AZ-NX-MDL-01237086		Double Hearsay; Hearsay; Relevance
1186	AstraZeneca document, Selling NEXIUM In a Highly Penetrated Managed Care Environment, Orange County DSMs	04/01/2002	AZ-NX-MDL-01235551	AZ-NX-MDL-01235558		Double Hearsay; Hearsay; Relevance
1187	TargetRx, Inc. presentation, Launch Tracking for Nexium - Wave 17, prepared for AstraZeneca	05/28/2002	AZ-NX-MDL-01237229	AZ-NX-MDL-01237302		Hearsay; Relevance; Unfairly Prejudicial
1188	Presentation by Dr. Gralnek. Preventing Recurrent Esophageal Erosions: The Benefits of Maintenance Therapy.	03/01/2003	AZ-NX-MDL-01233004	AZ-NX-MDL-01233040		Double Hearsay; Hearsay; Relevance
1189	Presentation by Dr. Gralnek. Severity of GERD Symptoms and Disease: The Complex Relationship Between Symptoms and Erosions.	03/01/2003	AZ-NX-MDL-01233041	AZ-NX-MDL-01233077		Hearsay; Relevance
1190	Astra presentation. NEXIUM® Top 10.	10/01/2003	AZ-NX-MDL-01232503	AZ-NX-MDL-01232515		Hearsay; Relevance
1191	Statement by D. Levine, M.D., representing AstraZeneca, to the Oregon Health Resources Commission	04/16/2004	AZ-NX-MDL-01232622	AZ-NX-MDL-01232629		Hearsay; Relevance
1192	E-mail from C. Watson to K. Fagge-Stephenson with attached TAK-390 MR / Dexlansoprazole slides	03/12/2008	NEX-RBX 3481140	NEX-RBX 3481185		Hearsay
1193	AstraZeneca Formulary Submission Dossier, NEXIUM® (esomeprazole magnesium) Delayed-Release Capsules	undated	AZ-NX-MDL-01231555	AZ-NX-MDL-01231974		Hearsay
1194	AstraZeneca Core Visual Aid	undated	AZ-NX-MDL-01232336	AZ-NX-MDL-01232361		Double Hearsay; Hearsay; Relevance
1195	Reprint of Kahrilas PJ, Falk GW, Johnson DA, et al. Aliment Pharmacol Ther. 2000;14:1249-58	undated	AZ-NX-MDL-01232369	AZ-NX-MDL-01232380		Hearsay; Relevance
1196	Reprint of Richter JE, Kahrilas PJ, Johanson J, et al. Am J Gastroenterol. 2001;96(3):656-65.	undated	AZ-NX-MDL-01232381	AZ-NX-MDL-01232392		Hearsay
1197	Astra presentation. Managing GERD Symptoms in the Geriatric Patient, version 25.	undated	AZ-NX-MDL-01232393	AZ-NX-MDL-01232423		Hearsay
1198	Astra presentation. PPI Treatment of GERD.	undated	AZ-NX-MDL-01232630	AZ-NX-MDL-01232705		Hearsay; Relevance
1199	Astra presentation. CVA Workshop.	undated	AZ-NX-MDL-01232987	AZ-NX-MDL-01233003		Hearsay
1200	AstraZeneca Annual Business Review presentation by C. Fitzsimons. Nexium® The leading PPI by value in 2005 and beyond	undated	AZ-NX-MDL-01237609	AZ-NX-MDL-01237621		Hearsay; Relevance
						Double Hearsay; Hearsay; Relevance

Page No.	Description	Date	Doc ID	End Doc	Additional Pages	REVISED OBJECTION
1201	Bell NJ, Burget D, Howden CW, et al. Digestion. 1992;51(Suppl 1):59-67.	01/01/1992	KESSELHEIMNEXMA000199	KESSELHEIMNEXMA000207		Hearsay
1202	Bate CM, Booth SN, Hepworth-Jones B, et al. Aliment Pharmacol Ther. 1993;7:501-7.	06/01/1993	[no bates]			Hearsay
1204	Chang M, Tybring G, Dahl M-L, et al. Br J Clin Pharmacol. 1995;39:512-8.	01/01/1995	[no bates]			Hearsay
1206	Gan KH, Geus WP, Lammers CB, Heijerman HG. Dig Dis Sci. 1997;42(11):2304-9.	11/01/1997	[no bates]			Hearsay
1207	Andersson T, Holmberg J, Rohss K, Walan A. Br J Clin Pharmacol. 1998;45:369-75.	01/01/1998	[no bates]			Hearsay
1208	Adams KF. Amer Heart J. 1998;136:753-8.	11/01/1998	KESSELHEIMNEXMA000296	KESSELHEIMNEXMA000301		Hearsay
1210	Feigelson RP, Rhim E, Bellaiwa W, et al. Am J Med. 1999 Aug;107:149-52.	08/01/1999	ABRAMSONNEXMA000058	ABRAMSONNEXMA000061		Hearsay
1211	Kahrilas PJ, Falk GW, Johnson DA, et al. Aliment Pharmacol Ther. 2000;14(10):1249-58.	01/01/2000	ABRAMSONNEXMA000261	ABRAMSONNEXMA000270		Hearsay
1212	Lind T, Rydberg L, Kyleback A, et al. Aliment Pharmacol Ther. 2000;14(7):861-7.	01/01/2000	KESSELHEIMNEXMA000162	KESSELHEIMNEXMA000168		Hearsay
1216	Thitiphae S, Talley NJ. Int J Clin Pract. 2000;54(8):537-41.	10/01/2000	KESSELHEIMNEXMA000004	KESSELHEIMNEXMA000008		Hearsay
1217	Veldhuyzen van Zanten S, Lauritsen K, Delchier JC, et al. Aliment Pharmacol Ther. 2000;14(12):1605-11.	12/01/2000	KESSELHEIMNEXMA000343	KESSELHEIMNEXMA000349		Hearsay
1218	Andersson T, Åkesson K, Hassan-Alin M, et al. Gastroenterology. 2000;118(4 Pt 2):A1210.	12/31/2000	[no bates]			Hearsay
1219	Andersson T, Hassan-Alin M, Hasselgren G, et al. Clin Pharmacokinet. 2001;40(6):411-26.	01/01/2001	KESSELHEIMNEXMA000009	KESSELHEIMNEXMA000024		Hearsay
1220	Hasselgren G, Hassan-Alin M, Andersson T, et al. Clin Pharmacokinet. 2001;40(2):145-50.	01/01/2001	[no bates]			Hearsay
1222	Richer JE, Kahrilas PJ, Johanson J, et al. Am J Gastroenterol. 2001 Mar;96(3):656-65.	03/01/2001	KESSELHEIMNEXMA000218	KESSELHEIMNEXMA000227		Hearsay
1226	Tulasay Z, Kryszewski A, Dite P, et al. Eur J Gastroenterol Hepatol. 2001;13(12):1457-65.	12/01/2001	KESSELHEIMNEXMA000350	KESSELHEIMNEXMA000358		Hearsay
1227	National Survey of Physicians Part II: Doctors and Prescription Drugs. The Kaiser Family Foundation, March 2002. http://www.kff.org/rxdrugs/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=13965 . Accessed on July 25, 2007.	03/01/2002	ABRAMSONNEXMA000062	ABRAMSONNEXMA000070		Hearsay
1228	RÅfhs K, Hasselgren G, Hedenström H, Dig Dis Sci. 2002;47(5):954-6.	05/01/2002	KESSELHEIMNEXMA000169	KESSELHEIMNEXMA000173		Hearsay; Relevance
1229	Steinbrook R. N Eng J Med. 2005 May 26;352(21):2150-2.	05/26/2002	ABRAMSONNEXMA000091	ABRAMSONNEXMA000093		Hearsay

Pl. Ex.	Description	Date	Depo	Exhib	Additional Bates	REVISID OBJECTION
1272	Arnold M. Med Market Media. 2007 Aug 9 2007. http://www.mmm-online.com/FDA-eyes-Nexium-Prilosec-for-heart-risks-with-ampquotyearly-communicationquot/article/24926/ . Accessed on September 6, 2011.	08/09/2007	ABRAMSONNEXMA000035	ABRAMSONNEXMA000035		
1274	Abrahamyan L, Johnson SR, Beyene J, et al. Rheumatology (Oxford). 2008;47(5):540-5.	02/02/2008	[no bates]			Hearsay; Relevance
1276	Zheng RN. World J Gastroenterol. 2009 Feb 28;15(8):990-5.	02/28/2009	KESSELHEIMNEXMA000249	KESSELHEIMNEXMA000254		Hearsay
1278	Katz MH. Arch Intern Med. 2010 May 10;170(9):747-8.	05/10/2010	[no bates]			Hearsay
1284	Doebler SA. Comparative Claims: Learning from FDA Warning and Untitled Letters. Regulatory Focus Online. 2012 Nov 9. http://www.raps.org/focus-online/news/news-article-view/article/2522/comparative-claims.aspx .	11/09/2012	[no bates]			
1289	Vacek D. Top 200 Drugs of 2002. Pharmacy Times. http://www.pharmacytimes.com/article.cfm?id=338 . Accessed on August 14, 2007.	undated	ABRAMSONNEXMA000016	ABRAMSONNEXMA000018		Authenticity; Hearsay
1290	FDA. Guidance for Industry, Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Rockville (MD): FDA; 1998 May.	05/01/1998	[no bates]			Hearsay; Relevance
1293	NDA 21-153. Gallo-Torres HE. Medical Officer's Review.	09/21/2000	NEX-RBX 0585755	NEX-RBX 0585930		Hearsay; Relevance
1294	NDA 21-153. Tsong Y, Gallo-Torres HE. Statistical Review and Evaluation (Clinical).	10/03/2000	AZ-NX-MDL-01238069	AZ-NX-MDL-01238106		Authenticity; Hearsay; Misleading; Relevance
1295	NDA 21-153. Fax from FDA to AstraZeneca with attached approvable labeling for Nexium.	10/04/2000	AZ-NX-MDL-01233765	AZ-NX-MDL-01233814		Hearsay; Relevance; Unfairly Prejudicial
1296	NDA 21-153. Other Background Information for Labeling Meeting.	10/27/2000	AZ-NX-MDL-01234147	AZ-NX-MDL-01234153		Hearsay; Relevance; Unfairly Prejudicial
1297	NDA 21-154. Hundley SG. Pharmacology/Toxicology Review and Evaluation.	10/31/2000	AZ-NX-MDL-01238064	AZ-NX-MDL-01238068		Authenticity; Hearsay; Misleading; Relevance
1298	NDA 21-153. Fax from FDA to AstraZeneca with attached revised clinical section of Nexium labeling.	12/07/2000	AZ-NX-MDL-01234457	AZ-NX-MDL-01234471		Hearsay; Relevance; Unfairly Prejudicial
1299	NDA 21-154. Meyer JM, Higgins K. Clinical and Statistical Review.	12/15/2000	RAN-ESM0076804	RAN-ESM0076843 RAN-ESM0076874 - RAN-ESM0076880; RAN-ESM0076844 - RAN-ESM0076873; RAN-ESM0076881 - RAN-ESM0076996		Incomplete; Authenticity; Hearsay; Relevance
1300	Approvable Letters for NDA 21-153 and NDA 21-154. http://www.accessdata.fda.gov/drug_satfda_docs/nda/2007/21154_Nexium_Approv.pdf	12/15/2000	[no bates]			Authenticity; Hearsay

Case#	Description	Date	Ref Doc	End Date	Additional Dates	REVISED OBJECTION
1301	NDA 21-153, General Correspondence: Response to FDA Labeling Revisions dated February 1, 2001.	02/05/2001	AZ-NX-MDL-01234841	AZ-NX-MDL-01234878		Hearsay; Relevance; Unfairly Prejudicial
1302	NDA 21-153, General Correspondence: Revised Draft Nexium Label	02/08/2001	AZ-NX-MDL-01234879	AZ-NX-MDL-01234911		Hearsay; Relevance; Unfairly Prejudicial
1305	NDA 21-153, Approved label for NEXIUM. http://www.accessdata.fda.gov/drug_satfda_docs/label/2001/211531bl.pdf	02/20/2001	[no bates]			
1306	NDA 21-153, Response to FDA's February 20, 2001 Request for Introductory Promotional Materials.	03/13/2001	NEX-RBX 0438902	NEX-RBX 0439132		Authenticity; Hearsay; Relevance
1307	NDA 21-153, General Correspondence: February 6, 2001 Sponsor Meeting Minutes (Labeling Discussions)	03/15/2001	AZ-NX-MDL-01235069	AZ-NX-MDL-01235134		Hearsay; Relevance; Unfairly Prejudicial
1308	NDA 21-153, FDA response to proposed promotional materials.	03/16/2001	AZ-NX-MDL-01232362	AZ-NX-MDL-01232368		Hearsay; Relevance
1309	FDA, Guidance for Industry, E 10 Choice of Control Group and Related Issues in Clinical Trials. Rockville (MD): FDA; 2001 May.	05/01/2001	[no bates]			Authenticity; Hearsay
1311	NDA 20-838, Approved label for ATACAND. http://www.accessdata.fda.gov/drug_satfda_docs/label/2002/20838s01s1b.pdf	09/13/2002	[no bates]			Authenticity; Hearsay; Relevance
1312	NDA 20-884, Letter from FDA DDMAC to Boehringer Ingelheim Pharmaceuticals, Inc.	03/22/2005	[no bates]			Authenticity; Hearsay; Relevance
1314	FDA, Guidance For Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products - Content and Format. Rockville (MD): FDA; 2006 Jan.	01/01/2006	[no bates]			Authenticity; Hearsay
1315	U.S. Government Accountability Office, Prescription Drugs, Improvements Needed in FDA's Oversight of Direct-to-Consumer Advertising. GAO-07-054. Washington (DC): U.S. Government Accountability Office; 2006 Nov.	11/16/2006	[no bates]			Authenticity; Hearsay; Relevance
1317	Temple RJ (Deputy Center Director for Clinical Science, CDER, FDA). Comparative Effectiveness Research. Presentation at FDA/DIA Statistics Forum. 2010 Apr 21.	04/21/2010	[no bates]			Authenticity; Hearsay; Relevance

Exhibit	Description	Date	Exhibitor	Endorsement	Additional Information	Revised Introduction
1318	Aiken KJ (DOMAC, OMP, CDER). An Introduction to the Regulation of Prescription Drug Promotion. The Role of FDA. Presentation at Medical Library Association Annual Meeting. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM26150.pdf .	05/24/2010	[no bates]			Authenticity; Hearsay; Relevance
1319	Kiester M (Associate Director of Operations, DOMAC). DOMAC Submissions. Presentation. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ForMakers/SubmittingMakers/UCM26150.pdf .	02/09/2011	[no bates]			Authenticity; Hearsay; Relevance
1320	Update to FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. March 23, 2011. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. May 25, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm .	03/23/2011	[no bates]			Authenticity; Hearsay; Relevance; Unfairly Prejudicial
1321	NDA 20-541. Approved label for ARIMDEX, reference ID: 2930800. http://www.accessdata.fda.gov/drug_satfda_docs/label/2011/020541s0261b1.pdf .	04/18/2011	[no bates]			Authenticity; Hearsay; Relevance
1322	Glossary of Terms. Drugs@FDA. U.S. Food and Drug Administration website. Last updated on February 2, 2012. http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm . Accessed on August 19, 2013.	02/02/2012	[no bates]			Authenticity; Hearsay
1324	Abrams T (Director, Office of Prescription Drug Promotion). OPDP Update on Oversight of Prescription Drug Promotion. Presentation. http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/cder/ucm330855.pdf .	10/01/2012	[no bates]			Authenticity; Hearsay; Relevance

Pl. Ex.	Description	Date	RegDot	EndDot	Additional Bates	REVISED OBJECTION
1326	Nexium, Drug Details, Drugs@FDA, U.S. Food and Drug Administration website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=search.Set_Current_Drug&ApplicationNo=021153&DrugName=NEXIUM&ActiveIngredient=ESOMEPRAZOLE%20MA NESIUM&SponsorApplicants=ASTRA ZENECA&ProductMktStatus=1&goto=Search.DrugDetails . Accessed on August 19, 2013.	08/19/2013	[no bates]			Authenticity
1327	NDA 22-307, Approved label for EFFIENT, reference ID: 3391282. http://www.accessdata.fda.gov/drug_satfda_docs/label/2013/022307s008b1.pdf	10/16/2013	[no bates]			Authenticity; Hearsay; Relevance
1328	21 CFR Â§ 201.56	undated	[no bates]			Authenticity; Hearsay; Relevance
1329	21 CFR Â§ 201.57	undated	[no bates]			Relevance
1330	21 CFR Â§ 202.1	undated	[no bates]			Relevance
1331	21 CFR Â§ 314	undated	[no bates]			Hearsay; Incomplete
1332	21 U.S.C. Â§ 355	undated	[no bates]			Hearsay; Incomplete
1333	40 Fed. Reg. 58,794	12/18/1975	[no bates]			Relevance
1334	44 Fed. Reg. 74,817	12/18/1979	[no bates]			Relevance
1335	60 Fed. Reg. 52,196	10/05/1995	[no bates]			Relevance
1336	71 Fed. Reg. 3,922	01/24/2006	[no bates]			Relevance
1337	Tov A (Arnold & Porter), FDA Regulation of Advertising and Promotion. Presentation at Regulatory Affairs Professional Society: Regulatory Affairs Certification (RAC) Study Group. http://www.arnoldporter.com/resources/documents/RAPS%20-%20FDA%20Regulation%20of%20Advertising%20and%20Promotion.pdf	07/14/2013	[no bates]			
1338	Screenshot from www.everythingbutanchoovies.com/everythingbutanchoovies/sample_launch/NEX/index.html . Accessed on August 8, 2013.	08/08/2013	[no bates]			Authenticity; Hearsay; Relevance
1339	Letter from FDA to National Association of Boards of Pharmacy. Therapeutic Equivalence of Generic Drugs. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm073224.htm	04/16/1997	[no bates]			Authenticity; Hearsay; Relevance
1340	Astra Pharmaceuticals memorandum from D. DiAmico to Everest EE Working Group	01/27/1999	NEX-RBX 2885503	NEX-RBX 2885503		Authenticity; Double Hearsay; Hearsay
1341	Appendix Table 1 to Declaration of Aaron S. Kesselheim	08/23/2013	[no bates]			Hearsay; Incomplete; Relevance
1342	Appendix Table 2 to Declaration of Aaron S. Kesselheim	08/23/2013	[no bates]			Hearsay

Index	Description	Date	RegDoc	ExtDoc	Additional Bates	REVISED OBJECTION
1404	DMF No. 18559, Module 3.2.S.4, Control of Drug Substance.	08/03/2005	RAN-ESM0001969	RAN-ESM0001979		Incomplete; Relevance
1405	DMF No. 18559, Module 3.2.S.4, Annexure-3, Certificates of Analysis.	08/03/2005	RAN-ESM0002234	RAN-ESM0002243		Incomplete; Relevance
1406	DMF No. 18559, Module 3.2.S.5, Reference Standards and Annexure-1, Spectroscopic Data of Working Standard of Active Substance.	08/03/2005	RAN-ESM0002248	RAN-ESM0002260		Incomplete; Relevance
1407	DMF No. 18559, Amendment.	06/29/2006	RAN-ESM0009359	RAN-ESM0009456		Incomplete; Relevance
1408	DMF No. 18559, Amendment, Submission letter, amendment (without annexures), and list of annexures.	08/17/2007	RAN-ESM0009457	RAN-ESM0009476		Incomplete; Relevance
1409	DMF No. 18559, Amendment, Annexure-VII, Specifications and Analytical Methods of Intermediates.	08/17/2007	RAN-ESM0009826	RAN-ESM0009863		Incomplete; Relevance
1410	DMF No. 18559, Amendment, Annexure-XI, Certificates of Analysis.	08/17/2007	RAN-ESM0009979	RAN-ESM0009988		Incomplete; Relevance
1411	DMF No. 18559, Amendment, Annexure-XII, Stability Data.	08/17/2007	RAN-ESM0009989	RAN-ESM0009995		Incomplete; Relevance
1412	ANDA No. 78-003, Submission letter, Table of Contents, Section I, Signed Application Form, Section II, Basis for ANDA Submission.	11/23/2005	Teva-ESO-000076	Teva-ESO-000106		Incomplete; Relevance
1413	ANDA No. 78-003, Section III, Patent Certification and Exclusivity Statement.	11/23/2005	Teva-ESO-000107	Teva-ESO-000112		Authenticity
1414	ANDA No. 78-003, Section IV, Comparison between Generic Drug and Reference Listed Drug.	11/23/2005	Teva-ESO-000113	Teva-ESO-000119		Authenticity
1415	ANDA No. 78-003, Section V, Labeling.	11/23/2005	Teva-ESO-000120	Teva-ESO-000343		Authenticity
1416	ANDA No. 78-003, Section VI.3, In Vivo Studies.	11/23/2005	Teva-ESO-000469	Teva-ESO-000521		Authenticity
1417	ANDA No. 78-003, Section VI.6, Formulation Data.	11/23/2005	Teva-ESO-000634	Teva-ESO-000634		
1418	ANDA No. 78-003, Section VII, Components and Compositions Statements.	11/23/2005	Teva-ESO-000635	Teva-ESO-000640		
1419	ANDA No. 78-003, Section VIII.1, Raw Material Controls, Active Ingredient.	11/23/2005	Teva-ESO-000643	Teva-ESO-000705		Authenticity
1420	ANDA No. 78-003, Section IX, Description of Manufacturing Facility.	11/23/2005	Teva-ESO-000895	Teva-ESO-000911		
1421	Letter from FDA to Ivax Pharmaceuticals	01/23/2006	Teva-ESO-003508	Teva-ESO-003509		
1422	Letter from FDA to Ivax Pharmaceuticals	04/12/2006	Teva-ESO-003598	Teva-ESO-003601		
1423	Letter from FDA to Ivax Pharmaceuticals	05/05/2006	Teva-ESO-007012	Teva-ESO-007017		
1424	Letter from FDA to Ivax Pharmaceuticals	10/03/2006	Teva-ESO-076646	Teva-ESO-076648		
1425	ANDA No. 78-003, Amendment.	11/13/2006	Teva-ESO-011011	Teva-ESO-011071		Authenticity
1426	Letter from FDA to Ivax Pharmaceuticals	01/10/2007	Teva-ESO-146887	Teva-ESO-146890		

Case No.	Description	Date	Reg Doc	End Doc	Additional Cases	REVISOR OBJECTION
1427	Letter from FDA to Ivax Pharmaceuticals	05/11/2007	Teva-ESO-011073	Teva-ESO-011076		Authenticity
1428	ANDA No. 78-003, Amendment.	03/04/2008	Teva-ESO-011085	Teva-ESO-012552		
1429	ANDA No. 78-003, Amendment, Submission letter.	05/29/2008	Teva-ESO-012554	Teva-ESO-012558		
1430	Letter from FDA to Ivax Pharmaceuticals	08/05/2008	Teva-ESO-019405	Teva-ESO-019408		
1431	ANDA No. 78-003, Amendment.	08/25/2008	Teva-ESO-110770	Teva-ESO-110775		Authenticity
1432	ANDA No. 78-003, Amendment.	09/12/2008	Teva-ESO-016546	Teva-ESO-016684		Authenticity
1433	Letter from FDA to Ivax Pharmaceuticals	11/25/2008	Teva-ESO-016538	Teva-ESO-016545		
1434	ANDA No. 78-003, Amendment.	09/22/2009	Teva-ESO-019418	Teva-ESO-019419		
1435	ANDA No. 78-003, Amendment, Submission letter.	08/19/2011	Teva-ESO-019420	Teva-ESO-019428		
1436	ANDA No. 78-003, Amendment, Module 3.2.P.5.6, Justification of Specifications, XRD Study.	08/19/2011	Teva-ESO-021509	Teva-ESO-021516		
1437	ANDA No. 78-003, Amendment, Module 3.2.S.4.4, Batch Analysis.	08/19/2011	Teva-ESO-021608	Teva-ESO-021628		Authenticity
1438	ANDA No. 78-003, Amendment, Module 3.2.S.4.5, Justifications of Specification, Polymorphism Statement.	08/19/2011	Teva-ESO-021631	Teva-ESO-021632		Authenticity
1439	Letter from FDA to Ivax Pharmaceuticals	03/07/2012	Teva-ESO-019429	Teva-ESO-019432		Authenticity
1440	Letter from FDA to Teva	04/03/2012	Teva-ESO-019433	Teva-ESO-019436		
1441	Letter from FDA to Teva	09/26/2012	Teva-ESO-019445	Teva-ESO-019450		
1442	ANDA No. 78-003, Amendment, Letter	04/25/2013	Teva-ESO-146879	Teva-ESO-146886		Incomplete
1443	DMF No. 18821, Submission letter.	09/28/2005	DRLMDL 196511	DRLMDL 196511		
1444	DMF No. 18821, Modules 3.2.S.1 through 3.2.S.2.2.	09/28/2005	DRLMDL 196521	DRLMDL 196573		
1446	DMF No. 18821, Module 3.2.S.2.2, Description of Manufacturing Process and Process Controls.	09/28/2005	AZ-NX-MDL-01258592	AZ-NX-MDL-01258617		Authenticity; Hearsay
1448	DMF No. 18821, Module 3.2.S.4.4.	09/28/2005	DRLMDL 197258	DRLMDL 197265		
1449	DMF No. 18821, Amendment, Draft.	05/29/2012	Teva-ESO-048065	Teva-ESO-048078		Hearsay
1450	ANDA No. 78-279, Submission letter.	04/25/2006	DRLMDL 174559	DRLMDL 174561		
1451	ANDA No. 78-279, Original Submission.	04/25/2006	NEX-RBX 3417386	NEX-RBX 3421212		
1452	ANDA No. 78-279, Section VII, Components and Compositions Statements.	04/25/2006	DRLMDL 000486	DRLMDL 000503		
1454	ANDA No. 78-279, Section XV, Analytical Methods.	04/25/2006	NEX-RBX 3420400	NEX-RBX 3421029		
1455	ANDA No. 78-279, Amendment, Letter.	08/13/2007	DRLMDL 153698	DRLMDL 153713		Hearsay
1456	ANDA No. 78-279, Amendment, Exhibit-3	08/13/2007	DRLMDL 153731	DRLMDL 153740		
1458	ANDA No. 78-279, Amendment	02/22/2008	DRLMDL 006046	DRLMDL 006097		
1461	DMF No. 19192, Table of contents and Section A, Address File.	02/21/2006	NEX-RBX 3421215	NEX-RBX 3421223		Hearsay; Incomplete
1462	DMF No. 19192, Section F.1, Drug Description.	02/21/2006	NEX-RBX 3421277	NEX-RBX 3421304		Hearsay; Incomplete
1463	DMF No. 19192, Section F.3.1, Process Description.	02/21/2006	NEX-RBX 3421348	NEX-RBX 3421370		Authenticity; Hearsay; Incomplete

Index	Description	Date	Ref Doc	End Doc	Additional Dates	REVISIO OBJECTIO
1464	DMF No. 19192, Section G.1, Raw Materials, Specifications and Test Methods, Omeprazole USP.	02/21/2006	NEX-RBX 3421377	NEX-RBX 3421406		Authenticity; Hearsay; Incomplete
1465	DMF No. 19192, Section G.5.3, Spectral Data of Reference Standard/Working Standard.	02/21/2006	NEX-RBX 3421601	NEX-RBX 3421605		Hearsay; Incomplete
1466	DMF No. 19192, Section G.7.2, Drug Substance: Certificate of Analysis.	02/21/2006	NEX-RBX 3421762	NEX-RBX 3421768		Hearsay; Incomplete
1467	DMF No. 19192, Volume 3 of 3.	02/21/2006	NEX-RBX 3422246	NEX-RBX 3422491		Hearsay; Incomplete
1468	DMF No. 19192, Amendment.	01/28/2010	DRLMDL 152010	DRLMDL 152338		Hearsay; Incomplete
1469	DMF No. 19192, Amendment. Submission Letter and Volume 1.	08/19/2010	DRLMDL 163010	DRLMDL 163522		
1470	DMF No. 19192, Amendment. Section F.1.1, General Properties	08/19/2010	DRLMDL 163078	DRLMDL 163100		
1471	DMF No. 19192, Amendment. Section F.1.2, Structural Elucidation Report of Esomeprazole Magnesium [Amorphous Form].	08/19/2010	DRLMDL 163101	DRLMDL 163127		
1472	DMF No. 19192, Amendment. Section F.3.1, Process Description.	08/19/2010	DRLMDL 163131	DRLMDL 163152		
1473	DMF No. 19192, Amendment. Section G.4, Intermediates: Specifications and Test Methods.	08/19/2010	DRLMDL 163261	DRLMDL 163285		
1474	DMF No. 19192, Amendment. Section G.7.2, Drug Substance: Certificate of Analysis.	08/19/2010	DRLMDL 163388	DRLMDL 163395		
1475	DMF No. 19192, Amendment. Annexure-1, Executed Batch Production Records.	08/19/2010	DRLMDL 163638	DRLMDL 163765		
1476	DMF No. 19192, Amendment. Submission letter.	04/26/2012	DRLMDL 261755	DRLMDL 261755		
1477	DMF No. 19192, Amendment.	04/26/2012	DRLMDL 261427	DRLMDL 261700		
1479	DMF No. 19192, Annual Report.	04/05/2013	DRLMDL 219738	DRLMDL 219747		
1480	ANDA No. 77-830, Original Submission.	08/04/2005	RAN-ESM0002528	RAN-ESM0019817		Missing Image
1481	ANDA No. 78-003, Original Submission.	11/23/2005	Teva-ESO-000074	Teva-ESO-003507		
1483	ANDA No. 78-279, Sections I-IV.	04/25/2006	DRLMDL 000053	DRLMDL 000081		Authenticity; Hearsay
1484	DMF No. 18559, Amendment. Annexures I - VI.	08/17/2007	RAN-ESM0089477	RAN-ESM0089625		Relevance
1485	DMF No. 18559, Amendment. Annexures VIII - XI.	08/17/2007	RAN-ESM0089864	RAN-ESM0089979		Relevance
1486	ANDA No. 78-279, Amendment.	08/19/2011	Teva-ESO-021114	Teva-ESO-021632		
1487	DMF No. 19192, Section F.3.2, Final product packaging and labeling.	02/21/2006	NEX-RBX 3421371	NEX-RBX 3421375		
1488	DMF No. 19192, Amendment. Annexure-2.	08/19/2010	DRLMDL 163766	DRLMDL 163865		
1502	Nexium Strategic Plan	05/01/2000	NEX-RBX 3508252	NEX-RBX 3508269		Hearsay
1515	E-mail from E. Mittleberg to M. Koppa	10/03/2005	Teva-ESO-007361	Teva-ESO-007361		Hearsay
1518	Ranbaxy spreadsheet: FTF Forecast.	11/11/2005	RAN-ESM0192913	RAN-ESM0192941		Incomplete; Relevance; Hearsay
1520	Ranbaxy spreadsheet: Master Product Grid 2005.	12/05/2005	RAN-ESM0195737	RAN-ESM0195786		Incomplete; Relevance; Hearsay
1522	Ranbaxy spreadsheet: Esomeprazole Magnesium Capsules - Market Forecast and RPI Sales.	06/20/2006	RAN-ESM0194086	RAN-ESM0194105		Incomplete; Relevance; Hearsay

PT-EX	Description	Date	Reg Doc	End Date	Additional Bates	REVISOR OBJECTION
1523	E-mail from E. Stewart to T. Crew with attached Cipla Products Forecast spreadsheet	10/03/2006	Teva-ESO-084517	Teva-ESO-084517	Teva-ESO-084518.000001 - Teva-ESO-084518.000004	Authenticity; Incomplete
1525	AstraZeneca presentation. Building a Megabrand: Nexium, C, Preparing for Success in the U.S.	02/26/2007	NEX-RBX 0593902	NEX-RBX 0593968		
1526	Ranbaxy spreadsheet. Esomeprazole Magnesium Capsules - Market Forecast and RPI Sales.	04/06/2007	RAN-ESM0186098	RAN-ESM0186117		Incomplete; Relevance; Hearsay
1527	Ranbaxy spreadsheet. Esomeprazole Magnesium Capsules - Market Forecast and RPI Sales.	04/30/2007	RAN-ESM0134201	RAN-ESM0134220		Incomplete; Relevance; Hearsay
1528	E-mail from J. Todisco to J. Bindra with attached Authorized Generic Partnership, Merck - Ranbaxy slides	05/16/2007	RAN-ESM0233581	RAN-ESM0233589		Foundation; Hearsay; Relevance
1531	Presentation - Genesis Overview	10/29/2007	AZ-NX-MDL-01243707	AZ-NX-MDL-0124713		Cumulative; Hearsay
1532	E-mail from S. Rothwein to S. Barker with attached Genesis Overview presentation	10/29/2007	NEX-RBX 3514270	NEX-RBX 3514277		Hearsay
1534	E-mail from R. Barker to multiple recipients with attached Potential NEXIUM® AG Overview presentation	11/09/2007	NEX-RBX 3456118	NEX-RBX 3456128		Hearsay; Unfairly Prejudicial
1535	AstraZeneca presentation. Potential NEXIUM® AG Overview.	11/12/2007	NEX-RBX 3514135	NEX-RBX 3514144		Hearsay
1536	AstraZeneca presentation. 2008 Price Considerations.	12/07/2007	AZ-NX-MDL-00915610.000001	AZ-NX-MDL-00915610.000016		Hearsay; Unfairly Prejudicial
1539	Ranbaxy spreadsheet. Esomeprazole Magnesium Capsules - Market Forecast and RPI Sales.	02/01/2008	RAN-ESM0054544	RAN-ESM0054659		Incomplete
1540	Form 20-F, Teva Pharmaceutical Industries Limited, for the fiscal year ended December 31, 2007	02/28/2008	Teva-ESO-024055	Teva-ESO-024224		Relevance
1541	AstraZeneca presentation. Strategic Options for Nexium OTC.	02/29/2008	NEX-RBX 3428588	NEX-RBX 3428698		
1542	AstraZeneca spreadsheet. Assumptions in Nexium P&L, Moving from Base Case ABU submission [9/13/07] to the generic entry in April 1, 2008.	02/29/2008	NEX-RBX 3457467	NEX-RBX 3457473		Hearsay
1543	AstraZeneca spreadsheet. Assumptions in Nexium P&L, Moving from Base Case Budget (1/08) and ABU (10/07) submission to the generic entry in April 1, 2008.	03/05/2008	NEX-RBX 3432365	NEX-RBX 3432373		Hearsay
1544	AstraZeneca spreadsheet. Assumptions in Nexium P&L, Moving from February 2008 MLF submission to the generic entry in April 1, 2008.	03/05/2008	NEX-RBX 3432383	NEX-RBX 3432391		Hearsay
1545	AstraZeneca spreadsheet. Assumptions in Nexium P&L, Moving from February 2008 MLF submission to the generic entry in April 1, 2008.	03/07/2008	NEX-RBX 3432374	NEX-RBX 3432382		Hearsay
1548	E-mail from R. Barker to J. Brazzo	03/26/2008	NEX-RBX 3514303	NEX-RBX 3514303		Hearsay
1552	E-mail from S. Santacroce to multiple recipients	04/21/2008	RAN-ESM0092131	RAN-ESM0092138		Authenticity; Double Hearsay; Foundation; Hearsay; Unfairly Prejudicial; Relevance

Ex. No.	Description	Date	Exhibitor	Revised	Revised Object
1553	E-mail from M. McCourt to M. McCourt with attached Nexium Plan B - Working Session, Scenario Review and Discussion.	04/26/2008	NEX-RBX 3505839	NEX-RBX 3505850	Hearsay
1554	AstraZeneca memo. Minutes and Action Items from AZ/Ohm Meeting, May 6, 2008.	05/12/2008	NEX-RBX 3513641	NEX-RBX 3513643	Double Hearsay; Hearsay
1557	Ranbaxy spreadsheet. Esomeprazole DR Cap Pellets.	07/03/2008	RAN-ESM0188739	RAN-ESM0188762	Incomplete; Relevance; Hearsay
1558	E-mail from S. Pandit to J. Todisco with attached Esomeprazole Forecast spreadsheet	07/03/2008	RAN-ESM0207721	RAN-ESM0207727	Relevance; Hearsay
1560	E-mail from Venkatachalam to Punji re: FTF Products	02/13/2009	RAN-ESM 0488474	RAN-ESM 0488478	Foundation; Relevance
1561	AstraZeneca spreadsheet. Nexium Franchise Pricing (JAWP & WAC) by NDC, Jan. 2001 - July 2008.	04/13/2009	NEX-RBX 3524937	NEX-RBX 3524941	Authenticity; Hearsay
1563	E-mail from J. Todisco to Venkatachalam K with attached Paonta Priority List spreadsheet and Paonta Sahib Applications spreadsheet	04/21/2009	RAN-ESM 0470162	RAN-ESM 0470167	Authenticity; Hearsay
1564	Teva spreadsheet. Deal Esomeprazole DR Caps.	06/05/2009	Teva-ESO-081242.000001	Teva-ESO-081242.000017	Authenticity; Hearsay; Relevance
1566	Ranbaxy spreadsheet. Esomeprazole Forecast 8-28-09.	08/28/2009	RAN-ESM 0462697	RAN-ESM 0462725	Authenticity; Foundation; Hearsay
1567	AstraZeneca presentation. Genesis Update.	09/28/2009	AZ-NX-MDL-00946916.000001	AZ-NX-MDL-00946916.000003	Incomplete; Relevance; Hearsay
1568	Declaration of Joseph Todisco in Support of Ranbaxy Laboratories Limited's and Ranbaxy Inc.'s Motion to Intervene and Motion to Dismiss, Dkt. 21, No. 09-cv-00485 (M.D.N.C.)	10/08/2009	Dkt. 21, No. 09-cv-00485 (M.D.N.C.)		Double Hearsay; Hearsay; Misleading
1569	Teva spreadsheet. Potential Competition Exclusivity Forfeiture.	11/16/2009	Teva-ESO-047045	Teva-ESO-047045	Hearsay; Relevance; Misleading
1572	E-mail from ERR Chandrashekar to V. Bhaskar	11/04/2010	DRLMDL 222897	DRLMDL 222897	Authenticity; Foundation; Hearsay
1573	DRL spreadsheet. Esomeprazole Mg BC 04.01.11.	01/04/2011	DRLMDL 240924	DRLMDL 240946	Double Hearsay; Foundation; Hearsay
1574	E-mail from S. Shubhaya to S. Rao with attached esomeprazole model spreadsheet	01/06/2011	DRLMDL 179341	DRLMDL 179348	Unfairly Prejudicial
1575	Dr. Reddy's Labs Pre-Deal Brief "One-Pager" (Confidential) - Esomeprazole - Draft	01/10/2011	DRLMDL 179353	DRLMDL 179363	Authenticity; Hearsay
1576	Dr. Reddy's Laboratories Pre-Deal Brief "One Pager" (Confidential) - Esomeprazole	01/10/2011	DRLMDL 219178	DRLMDL 219189	
1577	AstraZeneca presentation. Brand LTFs.	06/20/2011	AZ-NX-MDL-00842410.000001	AZ-NX-MDL-00842410.000014	Hearsay
1578	Transcript of Investigational Hearing, Joseph Todisco, FTC File No. 0810171	09/14/2011	RAN-ESM 0631843	RAN-ESM 0631869	Hearsay; Double Hearsay; Unfairly Prejudicial; Improper Exhibit (deposition transcript); Relevance
1579	Transcript of Investigational Hearing, Venkatachalam Krishnan, FTC File No. 0810171	10/20/2011	RAN-ESM 0631870	RAN-ESM 0631882	Authenticity; Double Hearsay; Hearsay; Improper Exhibit (deposition transcript); Unfairly Prejudicial

Page #	Description	Date	Depot Doc	End Doc	Additional Bates	Revised Objection
1580	E-mail from M. Dawson to C. Proctor and G. Rowles with attached 2011 Q2RBU USLT Pre-Read, Key Brand Summary presentation	04/26/2012	AZ-NX-MDL-00847315	AZ-NX-MDL-00847316	AZ-NX-MDL-00847317 000001 - AZ-NX-MDL-00847317 000015	Hearsay
1581	E-mail from R. Prybolsky to M. Digons and J. Valentine with attached Nexium erosion scenarios summary spreadsheet and generic erosion analysis presentation	05/30/2012	AZ-NX-MDL-00906234	AZ-NX-MDL-00906234	AZ-NX-MDL-00906235 000001 - AZ-NX-MDL-00906235 000002; AZ-NX-MDL-00906236 000001 - AZ-NX-MDL-00906236 000009	Hearsay
1582	AstraZeneca presentation, Express Scripts & Medco, Nexium.	06/25/2012	AZ-NX-MDL-00895722 000001	AZ-NX-MDL-00895722 000018		Hearsay
1583	E-mail from S. Nichols to multiple recipients with attached NEXIUM 2013 - 2014, Preliminary Strategy presentation	07/31/2012	AZ-NX-MDL-00899291	AZ-NX-MDL-00899291	AZ-NX-MDL-00899292 000001 - AZ-NX-MDL-00899292 000010	Hearsay
1584	DRL spreadsheet, Coating Details - Esomeprazole Magnesium Delayed Release Capsules.	12/27/2012	DRLMDL 337541	DRLMDL 337592		Foundation; Relevance
1585	AstraZeneca spreadsheet, Nexium Capsule Product Contribution [2004 - 1H2013]	07/30/2013	AZ-NX-MDL-01231531	AZ-NX-MDL-01231531		Hearsay
1587	AstraZeneca presentation, NexiumA*, the first PPI developed as an isomer, Evolution beyond all PPIs.	undated	NEX-RBX 0576023	NEX-RBX 0576122		Hearsay; Incomplete
1590	AstraZeneca presentation, Company Plan B, Financial Impact & Options Considered.	undated	NEX-RBX 3432402	NEX-RBX 3432407		Hearsay; Unfairly Prejudicial
1591	Teva spreadsheet, Esomeprazole Tablets Summary.	06/05/2009	Teva-ESO-065243	Teva-ESO-065243		Incomplete; Authenticity, Foundation, Hearsay
1592	IMS Consulting report to PHRMA, Assessment of Authorized Generics in the U.S.	03/01/2006	[no bates]			Authenticity; Hearsay
1593	Federal Trade Commission report, Authorized Generic Drugs: Short-Term Effects and Long-Term Impact.	08/01/2011	[no bates]			Authenticity; Double Hearsay; Hearsay; Unfairly Prejudicial
1594	M. Darby and E. Karni, "Free Competition and the Optimal Amount of Fraud," <i>Journal of Law and Economics</i> , 16(1), 1973, pp. 67-88.	01/01/1973	[no bates]			Authenticity; Hearsay; Unfairly Prejudicial
1595	P. Nelson, "Advertising as Information," <i>The Journal of Political Economy</i> , 82(4), 1974, pp. 729-754.	01/01/1974	[no bates]			Authenticity; Hearsay; Unfairly Prejudicial
1596	A. Friedlander, C. Winston, and K. Wang, "Costs, Technology, and Productivity in the U.S. Automobile Industry," <i>The Bell Journal of Economics</i> , 14(1), 1983, pp. 1-20.	01/01/1983	[no bates]			Authenticity; Hearsay; Relevance
1597	C. Winston and F. Manneering, "Consumer Demand for Automobile Safety," <i>The American Economic Review</i> , 74(2), 1984, pp. 316-319.	01/01/1984	[no bates]			Authenticity; Hearsay; Relevance
1598	United States Congress, Office of Technology Assessment, "Pharmaceutical R&D: Costs, Risks and Rewards," <i>Washington D.C.</i> , 1993.	01/01/1993	[no bates]			Authenticity; Hearsay; Relevance

Page	Description	Date	Ref Doc	End Doc	Additional Dates	REVISED OBJECTION
1600	S. Berry, J. Levinsohn and A. Pakes, "Automobile Prices in Market Equilibrium," <i>Econometrica</i> , 63(4), 1995, pp. 841-890.	01/01/1995	[no bates]			Authenticity; Hearsay; Relevance
1601	S.F. Ellison, I. Cockburn, Z. Griliches, and J. Hausman, "Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins," <i>AND Journal of Economics</i> , 28(3), 1997, pp. 428-446.	01/01/1997	[no bates]			Authenticity; Hearsay; Relevance
1602	Department of Justice and Federal Trade Commission, Horizontal Merger Guidelines, Apr. 2 1992, Revised Apr. 8, 1997.	04/08/1997	[no bates]			Authenticity; Hearsay; Relevance; Unfairly Prejudicial
1604	D. Balto, "Pharmaceutical Patent Settlements: The Antitrust Risks," <i>Food and Drug Law Journal</i> , 55, 2000, pp. 321-341 at 324-325.	01/01/2000	[no bates]			Authenticity; Hearsay; Unfairly Prejudicial
1605	D. Suh, W. Manning, S. Schoneimeyer, and R. Hadsall, "Effect of Multiple-Source Entry on Price Competition After Patent Expiration in the Pharmaceutical Industry," <i>Health Services Research</i> , 35(2), 2000, pp. 529-547.	01/01/2000	[no bates]			Authenticity; Hearsay; Relevance
1606	Federal Trade Commission News Release, "FTC Charges Drug Manufacturers with Stifling Competition in Two Prescription Drug Markets," March 16, 2000.	03/16/2000	[no bates]			Authenticity; Double Hearsay; Hearsay
1607	W. Emons, "Credence Goods Monopolists," <i>International Journal of Industrial Organization</i> , 19(3-4), 2001, pp. 375-389.	01/01/2001	[no bates]			Authenticity; Hearsay; Relevance
1608	E. Berndt, A. Bhattacharya, D. Mishol, A. Arcelus and T. Lasky, "An Analysis of the Diffusion of New Antidepressants: Variety, Quality, and Marketing Efforts," <i>The Journal of Mental Health Policy and Economics</i> , 5(1), 2002, pp. 3-19.	01/01/2002	[no bates]			Authenticity; Hearsay
1609	M. Rosenthal, E. Berndt, J. Donohue, R. Frank and A. Epstein, "Promotion of Prescription Drugs to Consumers," <i>New England Journal of Medicine</i> , 346(7), February 2002, pp. 498-505.	02/01/2002	[no bates]			Authenticity; Hearsay; Relevance
1611	U. Dulleck and R. Kerschbamer, "On Doctors, Mechanics, and Computer Specialists: The Economics of Credence Goods," <i>Journal of Economic Literature</i> , 44(1), 2006, pp. 5-42.	01/01/2006	[no bates]			Authenticity; Hearsay; Relevance

Item #	Description	Date	Page	Endor	Additional Dates	REV/DIOL/CTION
1612	B. Landon, M. Rosenthal, S. Normand, C. Spettell, A. Lessler, H. Underwood and J. Newhouse, "Incentive Formulary and Changes in Prescription Drug Spending," <i>The American Journal of Managed Care</i> , 13(6), June 2007, pp. 360-9.	06/01/2007	[no bates]			Authenticity; Hearsay; Relevance
1613	R. Larner, and C. Nelson, CRA International, "Market Definition in Cases Involving Branded and Generic Pharmaceuticals," <i>BBA Section of Antitrust Law, Economic Committee Newsletter</i> , 7(2), Fall 2007.	09/01/2007	[no bates]			Authenticity; Hearsay
1614	IMS, <i>The Uniform System of Classification (USC)</i> , Revised March 2008. http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/Health%20Services%20Research%20Network/USC_Classification_Process_2011.pdf .	03/01/2008	[no bates]			Authenticity; Hearsay; Relevance
1616	L. Kaplow, "Why (Ever) Define Markets?" <i>Harvard Law Review</i> , 124(437), 2010, p. 512.	01/01/2010	[no bates]			Authenticity; Hearsay
1617	Aitken, M.I. et al., "The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity," <i>INBER Working Paper No. 19487</i> , October 2013.	10/01/2013	[no bates]			Authenticity; Hearsay
1618	FDA, "Abbreviated New Drug Application (ANDA): Generics" (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/default.htm).	undated	[no bates]			Authenticity; Hearsay
1619	PDRhealth, <i>Physician Desk Reference</i> (http://www.pdrhealth.com/drugs/redum).	undated	[no bates]			Authenticity; Hearsay
1621	FDA, <i>Guidance for Industry, SUPAC-MR: Modified Release Solid Oral Dosage Forms</i> , Rockville (MD): FDA; 1997, Sep.	09/01/1997	[no bates]			Authenticity; Hearsay; Relevance
1622	Development Agreement between Ivax and Cipla	12/19/2002	Teva-ESO-066360	Teva-ESO-066373		Authenticity; Hearsay; Incomplete
1623	Supply Agreement between Ivax and Cipla	07/15/2003	Teva-ESO-030363	Teva-ESO-030383		Authenticity; Hearsay
1627	2004-2010 Projected Launch Dates for US Change Report.	01/31/2005	Teva-ESO-146887	Teva-ESO-146967		Authenticity; Hearsay
1630	E-mail from E. Mittleberg to M. Kopcha	10/03/2005	Teva-ESO-007931	Teva-ESO-007931		Hearsay
1633	Venkatachalam K. and G. Mehrotra with attached ANDA filings spreadsheet	12/19/2005	RAN-ESM0096778	RAN-ESM0096790		Relevance

P-1636	Description	Date	Reg Doc	Exhibits	Additional Bates	REVISED OBJECTION
1636	Inspectional Observations Form FDA 483, Dkt. 1-4, No. 08-cv-01764 (D. Md.)	02/25/2006	Dkt. 1-4, 08-cv-01764 (D. Md.)			Authenticity; Hearsay; Incomplete
1638	Form 20-F, Teva Pharmaceutical Industries Limited, for the fiscal year ended December 31, 2005	03/17/2006	[no bates]			Authenticity
1639	E-mail from S. Julie to J. Pott with attached letter	04/14/2006	Teva-ESO-023579	Teva-ESO-023581		Authenticity
1641	E-mail from R. Shetty to S. Drosatou	04/24/2006	Teva-ESO-007148	Teva-ESO-007148		Authenticity; Hearsay
1642	E-mail from R. Shetty to P. Jaworski	04/26/2006	Teva-ESO-007294	Teva-ESO-007294		Hearsay
1643	E-mail from J. Siga to B. Hobart	04/26/2006	Teva-ESO-082576	Teva-ESO-082576		Authenticity; Incomplete
1644	E-mail from R. Shetty to S. Drosatou	04/27/2006	Teva-ESO-007154	Teva-ESO-007155		Authenticity; Hearsay
1646	E-mail from R. Shetty to Z. Titi and response from S. Drosatou	05/03/2006	Teva-ESO-007160	Teva-ESO-007162		Hearsay
1647	E-mail from R. Shetty to S. Drosatou	05/04/2006	Teva-ESO-007163	Teva-ESO-007165		Hearsay
1648	E-mail from S. Drosatou to P. Jaworski	05/29/2006	Teva-ESO-076788	Teva-ESO-076790		Relevance; prejudice; Hearsay
1649	E-mail from J. King to S. Drosatou with attached Esomeprazole DR Caps forecast	05/30/2006	Teva-ESO-082852	Teva-ESO-082853	Teva-082856	
1650	E-mail from D. Stark to S. Julie	05/31/2006	Teva-ESO-033557	Teva-ESO-033559		Relevance; Hearsay
1651	Warning Letter 320-08-03 from FDA to Ranbaxy, Dkt. 1-5, No. 08-cv-01764 (D. Md. 2008)	06/15/2006	Dkt. 1-5, No. 08-cv-01764 (D. Md. 2008)			Misleading
1652	E-mail from T. Crew to E. Shohet with attached Cipla Summary presentation and Cipla Product Summary spreadsheet	09/07/2006	Teva-ESO-084754	Teva-ESO-084760		Authenticity; Incomplete; Relevance; Hearsay
1654	E-mail from S. Drosatou to P. Jaworski and M. Zamore with attached Ivax pipeline spreadsheet	09/25/2006	Teva-ESO-076764	Teva-ESO-076785		Authenticity; Relevance
1655	E-mail from M. Grewal to R. Lajekie with attached Minutes of Supply Chain/Regulatory/IP (SCRIP) Meeting held on 9/14/06	09/21/2006	RAN-ESMD158423	RAN-ESMD158443		Authenticity; Relevance
1657	E-mail from Venkatachalam K. to G. Mehrotra with attached October '07 monthly report for the US	11/07/2006	RAN-ESMD094360	RAN-ESMD094375		Hearsay
1658	AstraZeneca Competitive Price Sheet	01/01/2007	NEX-RBX 3431815	NEX-RBX-3431818		Authenticity; Hearsay; Unfairly Prejudicial
1659	E-mail from G. Mehrotra to multiple recipients with attached Region IVA Budget 2007 presentation	01/05/2007	RAN-ESMD172229	RAN-ESMD172995		Incomplete; Relevance; Hearsay
1661	Minutes of Supply Chain/Regulatory/IP (SCRIP) Meeting held on 2/1/07	02/26/2007	RAN-ESMD173586	RAN-ESMD173604		Authenticity; Incomplete; Foundation, Hearsay
1662	Teva spreadsheet. Forecast for Esomeprazole Magnesium DR 40 mg.	02/26/2007	Teva-ESO-135147.000001	Teva-ESO-135147.000005		Authenticity; Hearsay
1663	E-mail from S. Drosatou to M. Cavanaugh with attached Cipla New Product Launches - Status Update	03/28/2007	Teva-ESO-087735	Teva-ESO-087737		Authenticity; Hearsay
1664	E-mail from Z. Titi to S. Drosatou with attached Esomeprazole DR Capsules document	04/10/2007	Teva-ESO-075757	Teva-ESO-075759		Authenticity; Hearsay
1665	Letter from FDA to Ranbaxy approving ANDA No. 76-445 (Pravastatin Sodium Tablets)	04/23/2007	[no bates]			Authenticity; Relevance; Unfairly Prejudicial